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ABSTRACT 
PREDICTORS OF HEALTHCARE COST IN A WISCONSIN ACUTE LEUKEMIA 
POPULATION:  UTILIZATION OF A STATE-LEVEL ALL PAYER CLAIMS 
DATABASE 
 
by 
Patricia A. Steinert, MBA 
The University of Wisconsin-Milwaukee, 2012 
Under the supervision of Ron Cisler, PhD 
 
 
Understanding cost predictors of low incidence high cost cancers is increasingly 
important as the U.S. attempts to control health care costs. Acute myeloid and acute 
lymphoblastic leukemia are hematologic cancers requiring high cost care. 
Using Anderson’s model of health care utilization this study explores the 
influence of patient and community factors on health care costs.  Insurance claims cost 
data obtained from the Wisconsin Health Information Organization provided a sample of 
837 acute leukemia patients from April, 2009 and June, 2011.  Total, ancillary, inpatient, 
outpatient, pharmacy and professional services costs were analyzed using a GLM gamma 
log link regression model to identify cost predictors.  The added influence of patient and 
community enabling factors over patient characteristics and need for services was 
analyzed with hierarchical regression. 
Study findings include: (1) Predisposing characteristics of acute leukemia patients 
may not follow the commonly reported direction of cost where higher cost was associated 
with older age and female gender.  Instead their costs are expected to be higher in 
younger, male patients; (2) As expected, treatment with hematopoietic stem cell 
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transplant (HCT) and increased severity of disease represent significant cost drivers and 
strongly influence higher costs; (3) Community enabling resources influence cost where 
academic medical centers are associated with higher cost and providers located in areas 
of higher poverty are associated with lower cost; and (4) Costs related to different service 
types, i.e. inpatient, outpatient, etc., may not follow the same trends and result in 
important differences in findings.  While this creates complexity in assessing cost drivers 
it can provide the opportunity for cost interpretation and decision making specific to 
service type. 
Implications of study findings support the need for healthcare service research of 
rare diseases; further exploration of the relationship between treatment choice and cost as 
well as treatment disparities between providers and their locations; and the importance of 
clarity in service type cost. 
Future research opportunities would include linking cost data to clinical outcomes 
data; expanding the cost dataset longitudinally to accommodate more patient records 
along with a longer timeline of data for each; and sub analyses of potential interactions 
between variables. 
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CHAPTER 1:  Introduction  
1.1. Study Background.  
Rapidly increasing health care costs are a significant concern in the United States.  
In 2009, the Federal Centers for Medicare and Medicaid reported the costs associated 
with the health care sector of the U.S. economy accounted for 17.3% of the gross 
domestic product (GDP).  (www.cms.gov/National Health ExpendData)  At the same 
time, the U.S. has been reported to have one of the highest worldwide growth rates in 
health care spending increasing from 9% of GDP in 1980 to 16% of GDP in 2008 
(www.kff.org/insurance/snapshot). 
While the majority of Americans have health insurance, the number covered by 
private health care insurance is decreasing and the number covered by government health 
insurance or uninsured is increasing.  In September, 2011 the percentage of Americans 
with health insurance was reported at 256.2 million, 83.7% of the population.  Private 
health insurance accounted for 64% of all insured with 55.3% attributed to employer 
based programs, a number that has been decreasing since 2001. The percentage of 
Americans covered by government health insurance programs increased to 31%; 15.9% 
Medicaid and 14.5% Medicare.  The number of Americans without insurance increased 
to 49.9 million between 2010 and 2011, or 16.3 percent of the population 
(www.census.gov/hhes).  The Bureau of Labor Statistics report a 6% increase in 
individual healthcare spending between 2008 and 2010; primarily driven by a 10.8% 
increase in the cost of health insurance (www.bls.gov/news.release/cesan).   
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  Finding solutions for health care cost accountability, transparent reporting and a 
reduction of rapidly increasing health care costs is consistently noted as a high priority by 
many U.S. government leaders and agencies (www.acponline.org/advocacy; 
www.healthcare.gov; www.ahrq.gov/research).  The Patient Protection and Affordable 
Care Act, signed into law on March 23, 2010 by President Obama, has been designed to 
expand health care coverage, control health care costs and to improve the health care 
delivery system (www.kff.org/healthreform).  The new legislation is controversial and it 
is unknown if it will be effective in reducing the rate of growth in the health care market 
in the short or long term. 
1.2. Leukemia Cost. 
In Facts 2012 the Leukemia and Lymphoma Society report new cases of 
leukemia, lymphoma and myeloma are expected to represent nine percent of the 
approximate 1.6 million new cancer cases diagnosed in 2011 with 12.5 percent of new 
cases attributed to leukemia alone.  Diseases such as acute myeloid leukemia and acute 
lymphoblastic leukemia require high cost care in order to achieve long term, disease free 
survival.  Use of prolonged hospital care, high levels of medical technology and 
specialized health care services contribute to the high cost of treatment (Yu, 2006).  
Expensive chemotherapy regimens along with the potential for hematopoietic stem cell 
transplant create a continuum of cost starting from initial diagnosis through disease 
remission.  Ongoing oversight and maintenance treatments extend the use of health care 
services indefinitely.     
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1.3. Problem Statement. 
As the U.S. health care system debates policies to control health care cost, it 
becomes increasingly important to understand the drivers of high cost care.  Exploring 
cost predictors of low incidence, low prevalence but high cost cancers is important to 
both identify and better understand the underlying healthcare utilization and cost drivers.  
This study proposes to investigate both patient and community variables that may 
influence the cost of treatment of an acute leukemia population in Wisconsin.   
1.4. Study Objective and Specific Aims.  
The primary objective of this study is to explore the influence of certain patient 
demographic, provider demographic and socioeconomic variables on health care claims 
costs associated with a Wisconsin leukemia population identified within the State of 
Wisconsin all payer claims database and, through the utilization of this database, attempt 
to identify factors that are predictive of higher cost.  The study examines patients with the 
diagnosis of acute lymphoblastic leukemia, acute myeloid leukemia, and are present in 
the Wisconsin Health Information Organization (WHIO) database from April 1, 2009 
through June 6, 2011.   WHIO is an all payer claims database representing residents of 
the State of Wisconsin. An underlying objective of the study is to assess the usefulness of 
the WHIO datamart for cost research. 
In order to differentiate cost predictors related to service types, the study will 
examine claims costs associated with a the diagnosis of acute leukemia through six 
criterion variables: (1) Total claims cost; (2) Ancillary claims cost; (3) Inpatient claims 
cost; (4) Outpatient claims cost; (5) Pharmacy claims cost; and (6) Professional claims 
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cost.  The study will investigate both by billed cost (i.e., what is charged to the patient) 
and standard cost (i.e., a WHIO defined standardization definition) in an effort to 
determine if the two costs are different.  Diagnosis related claims costs are identified 
through WHIO defined episode treatment groups (ETG) and are the sum of all costs 
associated with the leukemia episode.  Throughout this paper, the diagnosis-cause cost 
analyzed in this study is referred to simply as ‘cost’.  The definition of the WHIO defined 
episode treatment groups is outlined in Appendix B.   
Whether cost is investigated using billed cost, standard cost or paid cost as a 
criterion variable is dependent on the perspective of the study.  A study that is interested 
in the patient perspective may use billed cost.   A study interested in using a closer 
definition to actual cost may choose standard cost.  A study that has a business 
perspective may use paid cost.  Billed cost, paid cost and standard cost is available in the 
WHIO datamart, but only billed cost and standard cost were available for use in this 
study.  Standard cost is calculated to adjust for variations related to insurance contracting, 
region and disease severity and comorbidity.  In a 1982 article, Finkler identifies the use 
of standard cost as best if the perspective of the study is real operational cost or resources 
used, but states that if the perspective of the study is the cost to the patient, billed cost is 
acceptable (Finkler, 1982).  While the patient perspective is considered important overall, 
use of standard cost is more common in health cost studies.   
The study has three specific aims:  
Aim 1:  To determine if patient predisposing characteristics of  age and gender, the 
patient need factors of treatment type and treatment episode severity and the enabling 
5 
 
 
 
resources of county of residence socioeconomics, type of payer, are predictive of cost.  In 
addition, to examine whether the type of health care provider, academic medical center or 
non-academic medical center, or its location socioeconomics are predictive of cost. 
Aim 2:  Using the optimal statistical model; to examine their influence on the cost 
criterions. 
Aim 3:  To investigate whether patient and community enabling resources; defined as 
provider type and location socioeconomics, patient enabling resources; defined as payer 
type and patient residence socioeconomics have added influence on cost over patient 
level predisposing characteristics: defined as age, gender and length of follow up and 
patient need; defined as episode treatment severity and treatment type.  
1.5. Scientific Significance. 
Prior theories of health care utilization identify patients need for care as a 
determining factor in use of health care services.  In addition, people who use more 
health care have been shown to incur more health care costs (Andersen, 1995).  An acute 
leukemia population will have a high need for healthcare, is expected to have high 
utilization of health care services and incur high cost.   These factors create a financial 
burden to the patient, the provider and the community.  Less understood are the patient 
and community factors associated with acute leukemia patients and their providers which 
may be predictive of higher cost.  Knowledge of key factors that influence these costs 
will benefit decision making at the patient, provider, and policy making level. 
Concern over increases in health care expenditures has created an immediate need 
to better understand costs and cost drivers in the health care system.  This study of low 
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incidence, high cost patients will provide needed information about groups that may not 
be immediately assessed.  Through the examination of factors that influence cost, this 
study will help identify if certain determinants can be used to better calculate the value of 
treatment for these diseases, allowing more informed resource allocation decision 
making. 
1.6. Research Questions and Hypotheses.  
This study uses data from an all payer claims database and multivariate regression 
modeling as a tool to identify whether patient characteristics, need and enabling factors 
and community factors are significant predictors of health care cost in a Wisconsin 
leukemia population.  Specific research questions are: 
1.   Does the patient’s age and gender, episode severity level, type of treatment and type 
of payer predict health care claims cost?  Does where a patient lives and the 
socioeconomics of their U.S. County of residence predict health care claims cost?  Do the 
type of provider and its location predict health care claims cost?  Are any variables more 
useful in predicting the claims cost criterion? 
Hypotheses:  A patient’s age, type of treatment, episode severity level is each expected to 
be significantly predictive of cost.  Increases in each of these factors have been shown to 
increase cost.  A public payer, lower patient socioeconomics and lower provider 
socioeconomics are also expected to be predictive of an increase in cost.  Finally, an 
academic provider is expected to have higher costs when compared to a community 
provider.   
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2.  How strong is the influence of each predictor on the cost criterion? 
Hypotheses:  While each is expected to be measurably predictive of the cost criterions, 
some variables, such as age, treatment, and disease severity level are expected to have a 
stronger influence when compared to others, such as payer type and gender. Provider 
type and location may have a slight influence on cost due to the differences in regional 
socioeconomics and organizational insurance contracting where higher costs are 
associated with academic medical centers and wealthier communities. 
3.  Does adding patient and community enabling resources, over and above patient 
predisposing characteristics and need for services predictors, significantly add to the 
predictability of the model, and if so, how strong is their influence? 
Hypotheses:  It is expected that, due to differences in patient’s healthcare insurance and 
socioeconomics as well as regional socioeconomics and insurance contracting, the patient 
and community enabling resources predictors will significantly add value to the model. 
 Health care cost data can be difficult to obtain as well as organize for research 
purposes.  An underlying intent of this study is to assess the usefulness of this type of 
administrative database to address health care cost research questions.  
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CHAPTER 2: Literature Review 
Studies of economic evaluation and health services were identified in a search 
through PubMed and the Cochran Collaboration between years 2004 through 2011.  (Key 
words:  acute lymphoblastic leukemia, acute myeloid leukemia, hematopoietic stem cell 
transplant, chemotherapy, economic evaluation, health care cost, health services cost 
methodology, zip code socioeconomics).   
2.1. Theoretical Framework. 
Prior health determinants research is used as a theoretical basis for this study.  
While the theories may not directly address cost as an outcome, its presence is implicit in 
the areas of access, quality and resource allocation.  Each theory supports the need to 
investigate and better understand the role of cost in health care utilization and decision 
making for the patient, provider and the community. 
2.2. Behavioral Models of Health Care Utilization. 
Aday proposed a comprehensive framework for health services research focusing 
on pathways that influence community and patient health outcomes (Aday, 2001).  This 
conceptual model incorporates both a community and patient perspective with a goal of 
integrating health services and public health research.  It integrates concepts of system 
structure and process, intermediate outcomes with a goal of an ultimate health outcome.  
In this model health policy, federal, state and local, is the highest level concept.  Level 
two relates to structural areas and includes the health care delivery system (availability, 
organization, financing), population at risk (predisposing, enabling, need) and 
environment (physical, social, economic).  Level three focuses on the process areas of 
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realized access to care (utilization, satisfaction) and health risk (environmental and 
behavioral).  Level four identifies the first intermediate outcome of effectiveness (clinical 
and population).  The second intermediate outcome level, five, is equity (procedural and 
substantive) and efficiency (production and allocative).  Level six is the final, ultimate 
outcome of health for both the patient and the community.  Each part of the conceptual 
model provides defined areas for health services research at both the patient and 
community level.  By including micro and macro level concepts, the framework provides 
the ability to investigate both the detail of an area of interest and then link it to the public 
health focus of community health. 
Aday used this conceptual base to create a framework for studying vulnerable 
populations.  In this model, the areas of focus include; social and economic policy, 
community oriented health policy, medical care and public health policy along with 
ethical norms and values.  Linkages between patient and community risk factors are 
illustrated along with variables that can be predictive of vulnerability for poor health 
outcomes. Health policy is identified as a mediator for the potential of positive versus 
negative health outcomes. 
Aday’s framework built on Anderson’s 1960’s Behavioral Model of Health 
Services Use which assessed determinants of health care utilization. (Anderson, 1968) 
With the intention of promoting equitable access to health services, Anderson (figure 2.1) 
investigated factors related to why families used health services.  This behavior model 
proposes that an individual’s use of health care can be attributed to certain individual and 
community or organizational predisposing factors that will either increase or decrease 
utilization.  Predisposing factors are related to biology; such as age and gender, social 
10 
 
 
 
structure; such as education, occupation, ethnicity, environment and culture, and, health 
beliefs; such as attitudes, values and knowledge.  In addition, both individual and 
community level resources are necessary to support the use of health care.  These include 
factors such as income, health insurance, transportation, and availability of health care 
personnel and facilities.   Finally, use of health care services will be influenced by the 
individual’s perceived/evaluated need for services as well as their ability to access to 
health care resources, work within the health care system and effectively manage their 
clinical problem.   
Figure 2.1 Anderson’s behavioral model 
Anderson, R.M. (1995). Revisiting the behavioral model and access to medical care:  Does it matter? 
Journal of Health and Social Behavior; Social Science Module, Mar, 36, 1. 
 
The models recognize that economic factors at both the individual and the 
community level, along with appropriate allocation of healthcare resources need to be 
addressed for improvement in population health. This study will further explore how 
patient, provider and community factors impact high utilization and costs of health 
services.  
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2.3. Health Services Utilization Database Research. 
In 2003, Hay investigated cost hospital cost drivers using state-level data.  
Utilizing data from a representatively large U.S. health insurance plan, this article 
identifies a number of characteristics that contribute to inpatient costs; local area per 
capita wages and incomes, characteristics of the physician market, hospital technology, 
and hospital occupancy and case-mix severity.   Other factors such as staff shortages and 
an economic slowing are noted to contribute to cost pressures. 
Schneeweiss and Avorn reviewed the utility of large healthcare databases for 
epidemiologic health care research, focusing on pharmaceuticals (Schneeweiss and 
Avron, 2005).  They conclude that electronic medical record systems have a great 
potential for research investigating comparisons, longitudinal data and clinical 
epidemiologic data.  They note that care must be given to the design of studies to allow 
for the system limitations and potential sources of bias such as incomplete records, 
miscoding, incorrect record linkage, etc.  As clinical detail and accountability increase, 
these systems are expected to become more useful to outcomes research.  
Motheral and her colleagues provide a checklist for retrospective database studies 
(Motheral, Brooks, Clark, Crown, Davey, Hutchins, Martin & Stang, 2003).  This article 
lists 27 questions that give guidance for designing a research study using a retrospective 
database specifically using medical claims or encounter databases.  These questions help 
to guide and decision about the study data, study methods and conclusions.  This study 
incorporated some of these conclusions into its study design, methods and conclusions. 
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2.4. U.S. Census Data and Socioeconomic Inequalities. 
 Geronimus and Bound in their 1998 article of using census-based aggregate 
variables as proxies for individual socioeconomics discuss the timing of census data, 
when it was collected, as well as the level of aggregation of the data (Geronimus and 
Bound, 1998).  They found that while investigators can comfortably use census data that 
can be up to 20 years old, it is limited in use for individual level interpretation.  They 
conclude that the aggregate variables available through geocoded data should not be 
viewed as proxies for the individual level construct because the aggregate variable will 
tend to be larger than the micro level variable due to biases related to correlation with 
other factors of the geographic region, i.e. income, race, etc.  These variables need to be 
interpreted as an area-based, rather than an individual-based, constructs. 
 Kreiger and colleagues as part of the Public Health Disparities Geocoding Project 
published a series of articles related to the usefulness of US census data to investigate US 
socioeconomic inequalities.  One of the articles investigated whether choice of area-based 
measurement or geographic level of measurement impact results of mortality and cancer 
incidence outcomes (Kreiger, Chen, Waterman, Soobader, Subramanian & Carson, 
2002a). Choice of area-based measures should be related to the geographic areas 
socioeconomic position (SEP) and defined through variable that could meaningfully 
summarize the area’s socioeconomic conditions and be robust over time and between 
regions.  Variables included; occupational class, income, poverty, wealth, education and 
crowding.  Geographic level was defined as census block, census tract and zip code.  
Results showed that measures of economic deprivation were most robust.   The authors 
identify the usefulness of area-based socioeconomic measures when used with 
13 
 
 
 
meaningful geographic concepts but not as proxies for individual socioeconomic data.  
They identify the U.S. census measure of ‘percentage of persons living below the US 
poverty line’ as a variable that meets the criteria of economic deprivation, meaningful 
across regions and over time, and easily understood.  In a separate 2002 article these 
authors discuss spatiotemporal difficulties associated with the use of zip code data and 
US census data.  The authors caution researchers using geocoded data to clearly identify 
any spatiotemporal mismatches between the study dataset and the U.S. census variable 
(Kreiger, Chen, Waterman, Soobader, Subramanian & Carson, 2002b).   
In 2005 Kreiger and colleagues investigated a method of routine monitoring of 
socioeconomic health disparities using census tract poverty data (Kreiger, Chen, 
Waterman, Rehkopf & Subramanian, 2005).  The percentage of persons living below the 
U.S. poverty line variable was used in census tract groups and provided a cost-efficient 
method of assessment that can be applied to health outcomes within the region and across 
the US.  The authors argue if the US public health surveillance data were geocoded, this 
method would provide a good mechanism for routine assessment of socioeconomic-based 
health disparities.  
2.5. Cancer:  Epidemiology and Cost. 
Cancer is the second most common cause of death in the U.S.; with an estimated 
577,000 deaths expected in 2012 (www.cancer.org/acs/groups). Cancer impacts the lives 
of over 11 million Americans; it does not discriminate by age, ethnicity, income or region 
(www.srab.cancer.gov).    
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Since the beginning of this century, the overall incidence and death rates of cancer 
have been decreasing; a result related to early detection, cancer prevention and better 
treatment options.  In The Annual Report to the Nation on the Status of Cancer, 1975-
2007, Kohler and colleagues found a decrease in the overall incidence of cancer in the 
U.S. population, but noted that due to the expected increase in life expectation the 
absolute number of individuals diagnosed with cancer is expected to increase creating an 
increase in demand for cancer related health care services (Kohler, Ward, McCarthy, 
Schymura, Ries, Eheman, Jemal, Anderson, Ajani & Edwards, 2011).  The authors point 
out the need for effective management of these diseases through not only prevention, 
detection treatment and survivorship but also the protection of resources necessary to 
provide good quality care. They conclude that utilization of quality population-based data 
systems and translation of evidence-based clinical and basic research findings are critical 
to sound public policy decisions for cancer. 
Using patient-reported demographic and socioeconomic data from the Social and 
Economic Supplement to the Census Bureau’s Current Population Survey, Clegg and 
colleagues reported cancer-related disparities linked to individual-level socioeconomic 
status for all combined cancers as well as the specific cancers of lung, breast, prostate, 
cervix and melanoma (Clegg, Reichman, Miller, Hanky, Singh, Lin, Goodman, Lynch, 
Schwartz & Chen, 2009).  Results showed, for each of the major cancer diagnoses, 
significant differences in incidence rates from self-reported data of education level, 
family income and poverty status.  The authors note the importance of differentiating 
between patient level characteristics and community level characteristics, particularly if 
measuring a similar construct such as socioeconomic status.  They conclude that social 
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disparities in cancer incidence may be related to socioeconomic and demographic 
differences in cancer-related risk factors and behaviors, that disparities in health care 
access may contribute to different types and stages of care and individuals with lower 
SES and educational level are more likely to have higher rates of cancer risk factors.   
The American Society of Clinical Oncology, Meropol and colleagues issued a 
guidance statement regarding the cost of cancer care (Meropol, Schrag, Smith, Mulvey, 
Langdon, Blum, Ubel & Schnipper, 2009).  The statement recognizes that while better 
prevention, detection and treatment have reduced the cancer death rate, costs of cancer 
treatment have steadily risen and continue to grow rapidly creating an unsustainable 
financial burden to all levels of cancer care.  The guidance statement makes the following 
recommendations:  recognizes that physician-patient discussions regarding cost of care 
are an important, a need for communication support tools for oncology providers related 
to cost of care, the development of educational resources about the high cost of cancer 
care.  This article identifies the need for a clear understanding of cost drivers in the 
cancer care system so that all patients can get access to, and are able to afford, high-
quality cancer care.  
In countries with centralized government managed health care, such as Canada, 
the Netherlands, Europe, there are studies that address the cost of diseases directed at the 
appropriate use of health care resources. However, the decentralized U.S. health care 
delivery system has made it challenging to assess health related costs for patients, 
organizations and populations.  The National Cancer Institute website reports a steady 
increase in U.S. spending for cancer care (www.cancer.gov).  A January, 2011 study 
from the Division of Cancer Control and Population Sciences projects the continued 
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increase in cancer care cost with the adoption of new, more advanced treatments as 
standards of care (http://progressreport.cancer.gov). 
Chang and colleagues estimated the cost of cancer for patients diagnosed with 
seven of the major types of cancer (Chang, Long, Kutikova, Bowman, Finley, Crown & 
Bennet, 2004).  This study found significant financial burden for cancer patients.  Within 
the groups studied, mean monthly cost of treatment ranged from $2,187 to $7,616 with 
cost driven by hospitalization and an average monthly loss of 2 work days.  In contrast, a 
non-cancer control was shown to have an average monthly cost of $329.  They note the 
viable use of administrative databases to estimate both direct and indirect costs.  
The most common forms of cancers are prostate, breast, lung, and colorectal 
cancer. Logically, they receive both higher levels of attention and, ultimately, funding.  
Cancers such as leukemia are as deadly to the patient and require expensive treatment.  
Health services research for cancers with lower incidence rates is important both to 
understand the financial burden of these diseases and to protect appropriate allocation of 
resources.  In 2010, the National Cancer Institute reported the direct cost of cancer care in 
the U.S. as $124.57 billion and the direct cost of care for leukemia was equal to $5.44 
billion, roughly 4.3% of total direct cost (www.cancer.gov/aboutnci/serving-
people/cancer-statistics).  
2.6. Epidemiology of Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. 
  Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) are 
cancers of the hematopoietic system, the system of the body which produces blood cells.  
These cancers are considered acute due to the rapid spread of disease; left untreated, they 
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will be fatal.  Common treatments for both diseases include chemotherapy, radiation and 
hematopoietic stem cell transplantation.   
Acute lymphoblastic leukemia (ALL) is a common hematopoietic cancer with an 
estimated 5000 cases diagnosed each year.  The Surveillance Epidemiology and End 
Results (SEER) website of the National Cancer Institute (NCI) reports the prevalence of 
ALL in the U.S. as of January 1, 2008 to be approximately 62,193 alive, 34,306 female 
and 27,887 male.  An estimated 20,300 individuals will be diagnosed with ALL in 2011; 
8,460 female and 11,840 male, with an estimated number of deaths equal to 5,800.  
Between the years 2004-2008 the overall median age at diagnosis for ALL was 13 years; 
approximately 60% of individuals diagnosed with the disease are under the age of 20 
years.  In children, the annual incidence of ALL is approximately 9-10 cases per 100,000 
with a median age at diagnosis between 2-5 years.  ALL accounts for 25% of all 
diagnosed childhood cancer and 75% of childhood leukemia. The overall reported 5-year 
survival for 2001-2007 was 64.4% with a median age at death between 2003-2007 being 
49 years of age (www.seer.cancer.gov/statistics).  Treatment of ALL includes 
chemotherapy, radiation and hematopoietic stem cell transplantation with all patients 
initially treated with chemotherapy.  Hematopoietic stem cell transplant is considered 
when disease recurs or when disease characteristics at diagnosis are such that the patient 
is unlikely to be cured with chemotherapy alone. Type and level of treatment is 
determined by factors such as patient age, white blood cell count at diagnosis, 
cytogenetics and disease status (i.e. whether in remission or with persistent leukemia 
despite chemotherapy).  In 2008 in the U.S., approximately 1000 allogeneic transplants 
were performed for patients diagnosed with ALL, roughly 430 for pediatric patients, 
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representing approximately 6% of all transplants performed 
(www.cibmtr.org/summaryslides). 
Acute myeloid leukemia is a hematopoietic cancer that begins in the bone marrow 
and impacts cells that would develop into white blood cells.  It is one of the most 
common forms of leukemia in adults with average onset around 60 years of age 
(www.seer.cancer.gov/statistics).  In 2011, 18,100 new cases were estimated to be 
diagnosed.  Of those diagnosed, 9,830 are men and 8,270 are women.  The number of 
deaths from AML in 2011 is estimated to be 9,320.  Between the years 2004-2008, SEER 
data report the median age at diagnosis of AML to be 67 years of age, with roughly 70% 
of all patients over the age of 55 with a 4.3/3.0 ratio of males to females.  The median age 
at death was 72 years of age with a male/female ratio of 3.6/2.2 per 100,000.  The years 
2001-2004 and 2004-2008 a slightly increasing trend was reported for both incidence 
(1.8% increase) and death (0.3% increase) in the AML population. 
Treatment of AML includes chemotherapy, radiation and the hematopoietic stem 
cell transplant.  Standard treatment of adult AML is dependent on the disease subtype but 
may include combination chemotherapy, high dose chemotherapy and stem cell 
transplant using either the patients cells (autologous transplant) or donor cells (allogeneic 
transplant).  As with ALL, type and level of treatment is determined by factors such as 
patient age, white blood cell count at diagnosis, cytogenetics and disease status, whether 
in remission or with persistent leukemia despite chemotherapy.  In the U.S. 
approximately 2500 transplants were performed for patients diagnosed with AML, 
slightly over 400 for pediatric patients, representing approximately 15% of all transplants 
performed (www.cibmtr.org/summaryslides). 
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2.6.1. Acute lymphoblastic leukemia treatment, survival and cost. 
Acute lymphoblastic leukemia is diagnosed more commonly in children versus 
adults.  Pui and Evans indicate that of the number of ALL cases diagnosed annually, 
roughly two thirds are from the pediatric population (Pui and Evans, 2006).  In children, 
the rate of 5 year survival is high, currently over 80%.  Assignment to the best therapy 
follows a strict assessment of relapse risk with a goal of avoiding high levels of toxicity 
but attaining a high cure rate.  Pediatric patients are grouped into the risk categories of 
standard, high and very high risk. 
ALL in adults is a challenging disease with a significantly lower rate of survival 
of less than 40% (Narayanan and Sami, 2011; Paulson, Szwajcer & Steftel, 2011; and 
Fielding, Richards & Chopra, 2007).  While most patients are able to achieve remission 
through treatment, most will eventually relapse.  Survival after relapse is reported to be 
10-20%.  Adult treatment options tend to follow the basic structure of the pediatric 
program; however, due to the poor survival rate after relapse, there is a current debate 
about the value of more aggressive treatment prior to relapse in the form of hematopoietic 
stem cell transplant (HCT).   
Schafer and Hunger compare the survival rate of adolescents and young adults 
(AYA) to both the pediatric and the adult population indicating that the AYA survival 
rate fall somewhere in the middle (Schafer and Hunger, 2011).  While there has been 
steady improvement in survival over the last few decades, they cite trials that show better 
survival for AYA’s following pediatric treatment regimens.  They conclude that future 
research should focus on socio-political and biological factors that may impact this 
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group.  Stock and colleagues discuss clinical and demographic differences between the 
AYA and the pediatric population which may account for differences in survival between 
the groups (Stock, La, Sanford, Bloomfield, Vardiman, Ganyon, Larson & Nachman, 
2008).  In a letter to the editor, Kantarjian and O’Brien suggest that an analysis of 
patterns of insurance coverage may be of interest in this group (Kantarjian and O’Brien, 
2009).  AYA’s may go through timeframes with no insurance coverage, affecting access 
and consistency of health care utilization.  
VanLitsenburg and colleagues provide a cost-effectiveness investigation of 
pediatric ALL in chemotherapy only regimens concluding that treatment was cost 
effective for patients in standard risk and medium risk groups (VanLitsenburg, Uyl-de 
Groot, Raat, Kaspers & Gempke, 2011).  Risk is mainly determined through levels of 
minimal residual disease.  However, high risk patients were excluded from the study due 
to their eligibility for hematopoietic stem cell transplant and represented approximately 
10% of the group.   
2.6.2. Acute myeloid leukemia treatment, survival and cost. 
Acute myeloid leukemia is the most common type of leukemia in adults.  
Deschler and Lubbert describe the epidemiology and etiology and identify it as a 
significant contributor to the number of cancer related deaths in the U.S. (Deschler and 
Lubbert, 2006).  For most patients the cause of disease is unknown, however age, genetic 
disorders and other hematologic disease have been reported as having a link to higher 
rates of mortality.  AML’s incidence rate is higher for males and occurs predominantly in 
adults, with over 80-85% of all cases reported in patients >15 years of age.  In adults, 
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AML tends to impact those >65 years of age, with over 42% reported cases.  Survival is 
reported to be 23% at five years if <55 and 11% if >55.  Untreated disease is always fatal.  
The improvement in supportive care options possibly has impacted the higher rates of 
survival over the years.  One conclusion of the authors identifies the ability to use 
population level databases as instrumental in the ability to detect differences because of 
the rarity of the disease 
Redaelli and colleagues provide a literature review of the economic burden of 
AML showing it to be a disease with a high cost of care affecting older adults (Redaelli, 
Botteman, Stephens, Brandt & Pashos, 2004).  With the aging population, incidence rates 
are expected to increase.  The review of the literature resulted in a selection of twenty 
nine studies that met the author’s inclusion criteria.  The studies offered a range of cost 
type, both indirect and direct, as well as cost comparison between different treatment 
regimens.  They note the lack of studies from a societal perspective and state this as a 
clear direction for future research. 
In an article investigating the cost–effectiveness of aggressive therapy after 
relapse in AML patients, Yu and colleagues compare a chemotherapy based treatment 
regimen to a hematopoietic stem cell transplant (HCT) based treatment regimen (Yu, 
Gau, You, Chern, Chau, Tzeng, Ho & Tsu, 2007).  AML is expensive to treat due to high 
rates of hospitalization and high cost treatments.  They conclude, that in patients <60, 
high dose chemotherapy only regimens estimated five year survival was higher than five 
year survival in the allogeneic transplant group.  In addition, it was more cost-effective in 
the chemotherapy only group with medium risk or lower.  However, they note that their 
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study is based on costs of care in Taiwan and results may not be transferable to Europe or 
the U.S., given the different cost structures between countries.  
2.7. Leukemia in Wisconsin. 
The Wisconsin Department of Health Services reports on leukemia but is not 
specific to AML and ALL.   Annually, approximately 832 Wisconsin residents were 
reported to be diagnosed with leukemia from 2002-2006 according to the National Center 
for Health Statistic’s Public Use Mortality file. In Wisconsin, leukemia is the most 
commonly diagnosed cancer under the age of 15.  Leukemia’s incidence rate was higher 
in males than in females (19.0 per 100,000 versus 11.0 per 100,000).  An average of 485 
deaths from leukemia was reported each year from 2002-2006; it is the leading cause of 
diseased based death in children under the age of 15, with higher mortality rates reported 
in males versus females (http://www.dhs.wisconsin.gov/wcrs/pdf/cancerwi0206.pdf). 
2.8. Chemotherapy. 
Chemotherapy is a treatment that uses chemical components to stop the growth of 
cancer cells.  Some leukemia’s are treated only with chemotherapy regimens designed 
using multiple factors such as type of disease, severity of disease, patient age, etc.  In 
AML, most patients begin treatment in induction chemotherapy with a goal of bringing 
the disease into remission.  If remission (CR1) is successful, most leukemia cells will be 
destroyed.  If it is unsuccessful additional chemotherapy treatment or hematopoietic stem 
cell transplant (HCT) may be necessary 
(www.marrow.org/patient/disease_and_treatment). 
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 In ALL, chemotherapy is the standard treatment for pediatric patients prior to 
first remission (CR1); however at first remission HCT becomes a viable treatment option.  
Adult ALL has not followed the same treatment guidelines as the pediatric group and 
HCT is an option at diagnosis.  In prior ALL studies reviewed, cost of chemotherapy was 
contrasted to cost of HCT.  The results of a 2007 study Orsi and colleagues concluded 
that allogeneic HCT for ALL patients in CR1 improved both event-free survival when 
compared to chemotherapy or autologous transplant and showed an acceptable level of 
cost-effectiveness (Orsi, Bartolozzi, Messori & Bosi, 2007).  However, Yu and 
colleagues in a cost analysis with an acute myeloid population concluded that the cost-
effectiveness of high dose chemotherapy treatment was comparable to allogeneic HCT in 
high risk patients, but in medium risk patients, high dose chemotherapy proved to be 
more cost-effective (Yu, Gau, You, Chern, Chau, Tzeng, Ho & Tsu, 2007).  In their 
conclusion, they identified the need for further research in the area given their sample 
size and cost differentiation.   VanLitsenburg and colleagues studied the influence of new 
medication and technology in a cost-effectiveness analysis of a pediatric ALL population 
treated with chemotherapy only regimens (VanLitsenburg, Uyl-de Groot, Raat, Kaspers 
& Gempke, 2011).  This study found treatment to be cost-effective in standard and 
medium risk patients.  Other chemotherapy cost studies compare newer drugs entering 
the market to those historically available.   (Hann, Stevens, & Goldstone, 1997; Kattan, 
Inoue, Giles, Talpaz, Olzer, Guilhot, Zuffa, Huber & Beck, 1996) 
2.9. Hematopoietic Stem Cell Transplant.  
Currently, hematopoietic stem cell transplant (HCT) is the only approved use of 
stem cells for disease treatment.  A hematopoietic stem cell (HSC) is a cell that has the 
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ability to produce new blood and immune cells and is found in the bone marrow, 
peripheral blood and umbilical cord blood.  Like normal HSC’s, malignant hematopoietic 
stem cells also have the capacity for self-renewal and are the cause of various leukemia’s.  
While chemotherapy can successfully treat, and eliminate cancer, in some cases more 
intensive treatment is required for a cure.  HCT is more intensive than chemotherapy; this 
treatment involves high-dose chemotherapy and irradiation followed by infusion of 
hematopoietic stem cells from a suitable related or unrelated donor.  Both normal and 
malignant stem cells are destroyed and the infusion of hematopoietic stem cells restores 
the content of the bone marrow in the person with ALL.  Despite the aggressive 
treatment, leukemic cells can persist or recur after HCT requiring further therapy, which 
may or may not be successful at disease eradication.    
The Healthcare Cost and Utilization Project (H-CUP) identified bone marrow 
transplant as the procedure with the most rapidly growing cost with aggregate costs 
growth of 84.9 percent between 2004 and 2007. (Stranges, Russo & Friedman, 2009)  
Prior research of cost and cost-effectiveness in hematopoietic stem cell transplant has 
investigated; the disease treatment (inpatient and outpatient); comparatively assessed the 
introduction of a new drug or therapy option (cord blood); and the ability to identify pre-
transplant characteristics that impact cost.  (Jacobs, Hailey, Turner & Maclean,2000; Lee, 
Klar, Weeks & Antin, 2000; Lin, Lairson, Chan, Du, Leung, Kennedy-Nassar, Martinez, 
Gottschalk,  Bollard, Heslop, Brenner & Krance, 2010; Majhail, Mothukuri & 
MacMillian, 2010; Saito, Cutler, Zahrieh, Soiffer, Ho, Alyea, Koreth, Antin & Lee, 2008)   
In a 2004 article, Gajewski and colleagues reviewed the relationship between providers 
and payers of HCT concluding that providers need to understand the true cost of care as 
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well as be able to identify predictable and unpredictable outlier risks (Gajewski, Foote, 
Tietjen, Melson, Simmons & Champlin, 2004). Ashfaq and colleagues recognized that 
detailed information available regarding HCT cost exists along with some cost 
effectiveness research, however, they state that there is limited evidence available related 
to adults and children with acute leukemia, noting the small size of the studies and their 
limited use for policy decision making (Ashfaq, Yahaya, Hyde, Andronis, Barton, Bayliss 
& Chen, 2010).  Other HCT cost studies have been limited to direct cost of treatment 
within a single center, some extending cost to 1 year or 2 years post treatment.  
Researchers have indicated a need for additional economic and quality of life studies. 
(Stephens, Gramegna, Laskin, Botteman & Pashos, 2005).  
During the 1990’s changes to clinical practice in HCT included the increased use 
of autologous transplantation, peripheral blood transplantation, outpatient treatment as 
well as the use of cord blood for donor cells.  Studies conducted during this timeframe 
investigated cost comparisons of these treatment related changes, concluding an overall 
reduction in cost with the new treatment options.  In a review of the literature, Pickard 
and colleagues provided a comprehensive review of studies relating to health related 
quality of life and economic evaluation in pediatric ALL (Pickard, Topfer & Feeny, 
2004). While some studies address disease specific economic burden and cost 
comparisons, most conclude that actual cost effectiveness analysis in the U.S. health care 
sector continues to be a challenge (Majhail, Mothukuri, Brunstein & Weisdorf, 2009; 
Redaelli, Botteman, Stephens, Brandt & Pashos, 2004). 
There have been significant advances in the clinical outcomes of hematopoietic 
stem cell transplant with a relatively large body of research investigating transplant 
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outcomes and new treatment cost effectiveness.  Bennett and colleagues showed 
decreasing cost related to the introduction of new donor options (Bennett, Waters, 
Stinson, Almagor, Pavletic, Tarantolo & Bishop, 1999). Other studies have provided 
detail of how to cost and overall cost of the procedure itself. (Majhail, Mothurkuri, 
Brunstein & Weisdorf, 2009; Westerman and Bennett, 1996; Waters, Bennett & Pajeau, 
1998).   Cordonnier and colleagues studied whether the use of reduced intensity treatment 
regimens were less costly (Cordonnier, Maury, & Esperou, 2005).  They found no 
significant reduction in cost due to the higher rates of infection and graft versus host 
disease in patients on the reduced intensity regimens.   
 Decision models for predicting long term outcomes and costs were reported by 
Costa and colleagues (Costa, McGregor, Laneuville & Brophy, 2007).   The study used a 
Markov decision analysis model in an adult population with acute leukemia and 
concluded that although initial transplant cost are high, the long term benefits of the 
transplant when compared to a non-transplant alternative, provided incremental cost 
effectiveness ratio (ICER) values that were both socially and financially acceptable.  
Saito and colleagues investigated costs of allogeneic HCT with high dose regimens 
(Saito, Cutler, Zahrieh, Soiffer, Ho, Alyea, Koreth, Antin & Lee, 2008).  This study 
provided detailed single institution cost of treatment, cost estimates for complicated and 
uncomplicated HCT procedures and costs for management of specific transplant related 
complications. 
In a 2010 study Lin and colleagues evaluated the cost and cost effectiveness of 
allogeneic peripheral blood stem cell transplantation compared to bone marrow 
transplantation in pediatric patients with acute leukemia (Lin, Lairson, Chan, Du, Leung, 
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Kennedy-Nassar, Martinez, Gottschalk,  Bollard, Heslop, Brenner & Krance, 2010).  This 
study concluded that comparative economic evaluation supported bone marrow transplant 
for standard-risk patients but indicated at lack of certainty for high-risk patients.  The 
ability to predict overall cost using pre-transplant patient characteristics was investigated 
by Lee and colleagues (Lee, Klar, Weeks & Antin, 2000). Their study was unable to 
identify pre-transplant characteristics; however it concluded that preventing clinical 
complications could significantly impact overall cost.   
 
 
 
 
 
 
 
 
 
 
CHAPTER 3:  Methods 
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 3.1. Design. 
This study is a cross-sectional secondary analysis of insurance claims data from 
the Wisconsin Health Information Organization for patients diagnosed with acute 
leukemia.   The active WHIO data mart contains 24 months of insurance claims data, 
collected over 27 months for completeness and refreshed approximately every 6 months.  
The study’s conceptual models are constructed using Anderson’s healthcare utilization 
model assumptions regarding the influence of patient predisposing characteristics, 
enabling resources and need (Figure 3.1).  Concept model 1 fits each predictor variable 
into the Anderson model and its relationship to each cost criterion.  Concept model 2 
presents the hierarchical relationship between the grouped variables and the cost 
criterion.  A quantitative analysis of the data is performed using multivariate regression 
methods, specifically generalized linear modeling (GLM).  Predictor variables have been 
identified and assessed in terms of their potential effect on the cost criterion variable 
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Figure 3.1.Concept Models. 
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3.2. Data. 
The Wisconsin Health Information Organization (WHIO) is a state-wide 
collaboration of insurance companies, health care providers, large employers and public 
agencies (www.wisconsinhealthinfo.org).  Starting in 2005, this group developed a State-
level database of health insurance claims in order to provide data useful for examining 
health care issues related to quality, efficiency and safety within the State of Wisconsin.  
Access to the data is available through the Wisconsin Health Information Organization 
Health Analytics Exchange (WHAE), a data base reporting system covering more than 
247.6 million insurance claims for care to roughly 3.8 million Wisconsin residents.  The 
exchange began collecting data in 2008 and provides access to a rolling 27 months of 
data; a total of 23.1 million episodes of care.  Version 6 of the data mart (DMV6) 
contains information for approximately 64.9% of the Wisconsin population.  Commercial 
claims represent 42% of the total, 25% are Medicaid FFS claims, 20% are Medicaid 
HMO claims and 13% are Medicare claims.  Additional detail regarding the DMV6 data 
is provided in Appendix A. 
The WHIO Health Analytics Exchange reporting system is designed for health 
care organization use, not specific to research, therefore limiting the types of research 
possible.  For the purposes of this study, the Wisconsin Medical Society (WMS) provided 
a core data set of all insurance claims for all patients with a diagnosis code of leukemia 
and lymphoma, DRG 200-208, in the DMV6 data.  Due to its size, the WMS data file 
was filtered to include only acute leukemia diagnoses.  Additional variables were 
obtained directly from the WHAE reporting system.  A relational database was created in 
Microsoft® Access 2010 and all variables were merged by patient ID to create the final 
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study dataset.  The study dataset was transferred to SAS 9.3, © SAS Institute, Inc., for 
data analysis. 
3.3. Sample. 
The study sample consists of WHIO database patients with a diagnosis of acute 
myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) coded at any time 
within the DMV6 data base.  The WHIO-DMV6 datamart includes a population of 
patients with claims submitted between the dates 4/1/2009 and 6/30/2011.  The initial 
dataset contained patients with any leukemia or lymphoma diagnosis which was further 
filtered to the specific diagnosis of acute AML and ALL.  Table 3.1 provides the 
description and diagnosis codes for this sample. 
Table 3.1. Lymphoma and Leukemia Diagnosis Codes. 
DRG code description Surgical code Medical code 
Lymphoma and leukemia without major 
O.R. procedure with mcc 
820  
Lymphoma and leukemia with major 
O.R. procedure with cc 
 
821  
Lymphoma and leukemia  with major 
O.R procedure without cc/mcc 
 
822  
Lymphoma and leukemia without major 
O.R. procedure with mcc 
 
 834 
Lymphoma and leukemia without major 
O.R. procedure with cc 
 835 
Lymphoma and leukemia without major 
O.R. procedure without cc/mcc 
 836 
CC-complications 
MCC-major complications 
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The datamart tracks patients by claims received and uses episode treatment 
groups or ETG’s (Table 3.2) that assign claims to both a specific diagnosis as well as a 
specific time of the event. Patients can be assigned up to three diagnoses in each episode 
of care and are included in the study if an acute leukemia diagnosis was present.  Service 
types are used to identify where the cost was generated, i.e. inpatient, outpatient, 
ancillary, professional or pharmacy.   
Table 3.2.Episode Treatment Group-ID; Leukemia Episode Treatment Group. 
ETG type ETG-ID 
Leukemia without surgery 85 
 
Leukemia with surgery 86 
 
Leukemia with active management 
without surgery 
 
87 
Leukemia with active management 
with surgery 
88 
 
The DMV6 data set provided claims for 12,504 unique patients with a lymphoma 
or leukemia DRG as the primary, secondary or tertiary diagnosis.   A further filter for the 
acute leukemia ICD-9 codes identified a sample of 837 unique patients with a diagnosis 
of acute lymphoblastic or acute myeloid leukemia. (Table 3.3)   
Table 3.3.ICD-9 CM Code for Acute Leukemia 
Diagnosis ICD-9 CM code 
Acute lymphoblastic leukemia 204.xx 
Acute myeloid leukemia 205.xx 
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The flow chart identifying datamart patients with acute leukemia is provided in 
Figure 3.2. 
Figure 3.2. Flow Chart of Acute Leukemia. 
 
 
 
 
 
 
 
3.4. Variables. 
Variables that were reviewed for inclusion into the study models are listed in 
Table 3.4.  Model variables are included based on their potential influences on healthcare 
cost on the patient and community level as well as their availability in the datamart.  
Healthcare outcomes are known to be influenced by patient and disease related along 
with treatment related factors. However, a limitation of the WHIO datamart is that it does 
not provide data specifically related to clinical outcome and the variables used in this 
study are limited to those available within the datamart.  Patient age and gender are 
included; unfortunately race is not available in the data base and cannot be included in 
Patients included in WHIO data 
mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of 
leukemia or lymphoma included in 
the WHIO DMV6 datamart   
(DRG 204-205) 
N=12,504 
Exclude patients with DRG’s other 
than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute 
leukemia  
N=837  
Exclude patients with non-acute 
diagnosis 
N=11,670 
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the analysis.  All study variables are assessed for their potential influence on healthcare 
cost through a review of prior literature. Each variable has been reviewed for definition 
within the database, availability and redundancy.  Overall availability and completeness 
of a variable has been assessed for its impact and usefulness for the study.  
3.5. Measurement.  
3.5.1. Criterion variable: cost. 
The criterion variable, cost, is defined by total cost, ancillary cost, inpatient cost, 
outpatient cost, pharmacy cost and professional cost. Cost data for the study is available 
in two ways: (1) Cost of service billed, defined as provider charges; and (2) Standard 
cost, defined through a standard pricing methodology that attempts to smooth out cost 
differences caused by factors such as contractual agreements and region.  Because this 
study is interested in both patient and community perspective the cost of services billed 
and the standard cost will be modeled in the analysis. The claims cost criterion is defined 
as a diagnosis-specific cost and represents all claims received for a patient where an acute 
leukemia diagnosis code has been used for any of the three diagnoses codes in the WHIO 
datamart.   All costs used in the study are associated with insurance claims and will be 
referred to simply as ‘cost’. 
3.5.2. Predictor variables. 
3.5.2.1. Predisposing characteristics  
Patient predisposing characteristics predictor variables of cost are defined as (1). 
Patient age (i.e., age recorded in the datamart); (2) Patient gender (i.e., gender recorded in 
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the datamart); and (3) Length of follow up (i.e., calculated as the difference in the number 
of days between the start of service date and end of service date). 
 Age has been linked to better outcomes in a number of studies.  (Deschler and 
Lubbert, 2006; Lee, et.al, 2000, Saito, Zahrieh, Cutler, Ho, Soiffer, Alyea & Lee, 2007)  
It has also been attributed to higher healthcare costs, with increasing age is associated 
with increasing costs, particularly in diseases prevalent in an older population.  Other 
studies have shown a gender difference in use of health care services, with females 
having a higher utilization rate, and subsequently, higher cost.  (Bertakis, Azari, Helms, 
Callahan & Robbins, 2000)  
Because this is a point in time sample, length of follow up variable is included in 
the regression model to control for differences in patient follow up within the datamart.  
Datamart differences in follow up may occur due to a variety of unrelated causes, for 
example, death, loss of insurance, movement out of the region or a late occurrence in the 
datamart.  (Diehr, Yanez, Ash, Hornbrook & Lin, 1999)  This is not a patient 
characteristic but the variable is grouped as a predisposing characteristic in order to 
control for the inherent differences in follow up present in the data.  A relationship to the 
need for resources group was explored but rejected due to the sample’s unknown 
underlying differences in cause.  
3.5.2.2. Patient Need. 
Patient need level predictor variables include:  (1) Treatment type (i.e., defined as 
chemotherapy only or chemotherapy plus HCT; and (2). Episode severity level (i.e., 
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ranked from 1-4 with 1=low severity, 2=low/medium severity, 3=medium/high severity 
and, 4=high severity). 
 Treatment of disease as well as disease severity level has the potential for 
significant influence on both clinical outcome and cost and is well documented in the 
literature.  (Ashfaq, et.al, 2010, Cordonnier, et.al, 2005, Jacobs et.al, 2000, Yu, et.al, 
2006)  Treatment type will be defined as chemotherapy plus allogeneic and autologous 
HCT or chemotherapy only.  Severity is calculated per episode of treatment and utilizes 
the patient’s comorbidities, prior healthcare use and prior types of services known in the 
datamart. Calculations for severity level are provided in Appendix E. 
3.5.2.3. Enabling resources 
Enabling resources predictor variables include:  (1) Patient county percent under 
poverty (i.e., defined by the ZIP code of patient’s County and the corresponding U.S. 
census reported % of residents from that county with income below poverty line and the 
US census reported % below poverty line); (2) Payer type (i.e., defined by public payer or 
private payer); (3) Provider type (i.e., defined by academic medical center or non-
academic medical center); and (5) Provider percent under poverty (i.e., defined by the 
ZIP code of provider location and the corresponding U.S. census reported % below 
poverty line).   
 The percent under poverty variable is used to assess individual level 
socioeconomic effects.  Clegg and colleagues reported a higher rate of late-stage cancer 
diagnoses with lower socioeconomic status (Clegg, et.al, 2009).  In 2009 study of HCT 
outcomes, Baker and colleagues found low income patients , i.e. <$36,400, had lower 
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probability of overall survival and higher probability of treatment related mortality when 
compared to higher income patients , i.e  >$56,000, (Baker, Davies, Majhail, Hassebroek, 
Klein, Ballen, Bigelow, Frangoul, Hardy, Bredeson, Dehn, Friedman, Hahn, Hale, 
Lazarus, LeMaistre, Lobreiza, Maharaj, McCarthy, Setterholm, Spellman, Trigg, 
Maziarz, Switzer, Lee, Rizzo, 2009).   While Geronimus and Bound state that U.S. 
census-based aggregate variables are not appropriate proxies for individual 
socioeconomic status, Krieger and colleagues conclude that they are meaningful 
measurements of area-based socioeconomics (Geonimus and Bound, 1998; Krieger, et.al, 
2005).  The percentage of persons living below the U.S. poverty line variable was 
identified as meeting the criteria for as a valid and useful socioeconomic measurement.  
In this study, all socioeconomic measures are area-based. 
In prior behavioral health studies, payer type has been shown to impact cost 
through differences in hospital length of stay.  (Sclar, et.al, 2008)  Because HCT is 
generally reimbursed as a bundled payment by insurance companies, public versus 
private sources of reimbursement may have an impact on initial treatment cost and may 
impact treatment costs over time.  Meropol and colleagues discuss the payer’s role in 
reducing health care expenditures and the need to use evidence-based decision making 
while determining cost efficiencies (Meropol, et.al, 2009).  In 2009, Kantarjian and 
O’Brien commented on the need to investigate the role of insurance policies in the young 
adolescent age group, noting the lack of coverage lending to lack of care over prolonged 
timeframes in this group (Kantarjian, et.al, 2009).  Specific to HCT, Gajewski and 
colleagues identify the need for consistent provider/payer dialogue to insure payer 
support for and patient access to this treatment option (Gajewski, et.al, 2004). 
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 A 2003 article of hospital cost drivers, J. Hay identifies overall economic activity 
of the community, price-level variation, hospital technology, hospital market and 
healthcare labor force as some of the factors associated with inpatient cost growth.  In 
this study, provider type is defined as academic medical center versus not academic 
medical center because of the expectation that academic medical centers will have a 
different cost structure than community hospitals (Hayes, 2003).  Yuan and colleagues 
conclude that while teaching not-for-profit hospitals had better clinical performance than 
other hospitals, they also had significantly longer length of stay (Yuan, Cooper, 
Einstadter, Cebul & Rimm, 2000). 
Provider ZIP code and % below poverty line is included to assess a community 
level geographic and socioeconomic effect.  Anderson’s behavioral model would predict 
a community socioeconomic influence on the cost outcome due to access to higher levels 
and quantity of health care services in more affluent socioeconomic locations.  The 
community SES measurement is based upon the location of the provider, its reported US 
census % of persons below the US poverty line.  The provider location is determined by 
the reported address of the provider in the WHIO database. The study variables are listed 
in Table 3.4. 
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Table 3.4 Description of Study Variables.
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3.6. Statistical Analyses.  
Use of administrative data bases to assess questions relating to health care cost 
can create data analysis challenges.  Because these databases are created for 
reimbursement rather than research, they generally have limited scope regarding detailed 
patient demographics, disruption in coverage, clinical outcomes and generally contain 
censored data. 
In a 1999 article, Diehr describes methods of analysis for health care cost and 
utilization (Diehr, et.al, 1999).  Multivariate regression is often used to identify cost 
predictors within groups. The authors discuss the one part model as most efficient when 
attempting to understand the effect of covariates on total cost because it creates a single 
regression coefficient for each variable and results are easily interpreted.  The article 
provides additional detail regarding skewed cost data, differences in types of cost, 
adjusting for different lengths of follow up and, death and censoring.  Barber and 
Thompson in a 2004 article discuss the use of generalized linear models (GLM) for the 
analyses of cost data rather than ordinary least squares (OLS) and identify the gamma, 
log link model as providing the best result.  They identify challenges inherent in the 
analysis of cost data because of a typical skewed distribution and the need to use 
estimates of mean costs.  Dodd and colleagues compared different multivariable 
regression models for analyzing cost data and found gamma with log link modeling 
provided the best result (Dodd, Bassi, Bodger & Williamson, 2006) .  
This study uses recommendations from these articles to fit the best method to the 
sample in order to analyze the study specific aims.  The final decision of the GLM 
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gamma log link model was made after an initial review of the study data and assessment 
of its fit with model assumptions.  SAS 9.3 software is used to analyze the multivariate 
regression models all tests will be considered significant at the 0.05 level. 
3.7. Complexity of Cost Data Analyses. 
 Analysis of cost data is complex due to the tendency of being right-skewed with 
long, right tails, due to;  (1) The presence of large numbers of low cost events in addition 
to a few very high cost events; (2) The lack of negative events; (3) The higher utilization 
of services due to more severe diagnosis; (4) The high cost of certain types of treatment; 
(5) Differences in follow up; and (6) Some patients utilize health services at a greater rate 
and are responsible for a higher proportion of heath care cost (Dodd, Bassi, Bodger, 
Williamson, 2006; Barber & Thompson, 2004; Basu & Manning, 2009; Lin, 2000).   
Estimates that are meaningful and easy to interpret are preferred by decision 
makers.  In economic or policy evaluation they will often rely on the differences in mean 
costs and whether the differences in the means between groups are statistically 
significant.  However, the use of arithmetic mean healthcare costs can be misleading due 
to the underlying nature of the data.  Highly skewed data will have medians that greatly 
differ from the means.  Barber and Thompson, 2004, describe the generalized linear 
models (GLMs) as useful for regression of cost models due to their flexible methods for 
the analysis of mean costs, the allowances for non-normal data distributions and the ease 
of interpretation of the results. 
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3.8. Generalized Linear Model (GLM). 
 Using Ordinary Least Squares (OLS) regression with cost data is problematic due 
to the non-normality of the data’s distribution which can result in a bias that may predict 
negative costs. The calculation of a log transformed outcome variable can solve the non-
normal distribution problem but provides a result that is difficult to interpret given that 
log transformed OLS estimates are differences in the transformed log cost, an outcome 
that is not of interest.  Generalized Linear Models (GLM) have been recommended for 
the analysis of cost data because they allow the advantages of a log link in the model but 
the differences in the mean outcome is estimated directly and statistical inferences are 
easier to interpret (Neal & Simons, 2007; Manning & Mullahy, 2001; Dodd, et.al, 2006; 
Basu, 2005; Manning & Mullahy, 2002).   
GLM’s are extensions of traditional linear models but characterize data through a 
link function (g) and a distribution family (F).  In a GLM the mean of the sample relates 
to a linear predictor through a nonlinear link function and the criterion probability 
distribution conforms to an exponential family of distributions. A GLM link function, 
such as log, logit, identity and inverse, characterizes the relationship of the raw 
untransformed criterion scale to the predictors, i.e. the relationship between the predictors 
and the mean criterion response variable.  The GLM family specifies the criterion 
distribution that reflects the mean-variance relationship where: 
 Gaussian = constant variance 
 Poisson = variance is proportional to the mean 
 Gamma = variance is proportional to the square of the mean 
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 Inverse Gaussian or Wald = variance is proportional to the cube of the mean 
GLM’s can have a variety of forms but the general form is: 
  g(µi) = xiβi + e, yi ~F,  
where µi is the expected mean value from the model, βi, are the regression coefficients, e 
is the error and F represents the models distribution function.  The criterion variable (Yi) 
is independent and has a probability distribution from an exponential family.  GLM 
accommodates skewed data through variance weighting of the criterion variable rather 
than transformation.  The variance of the criterion depends on the mean through a 
variance function V: 
  var(Yi) = ϕV(ui)/wi,  
where ϕ is a constant and w is a known weight for each observation.  If the weight is 
unknown, it is estimated.  Fitted generalized linear models are summarized through 
parameter estimates, standard errors, goodness-of-fit statistics, confidence intervals and 
hypothesis tests (Basu, 2005; Manning & Mullahy, 2001).   
3.8.1. GLM gamma log link model. 
 GLM’s fit the needs of health care cost analysis because of a focus on criterion 
means and flexibility in the selection of the distribution family.  Literature comparing the 
best GLM for use in health economic analysis routinely selects the gamma log link model 
as a candidate for providing the best fit for health care cost data.  (Dodd et.al, 2006; 
Barber & Thompson, 2004) The gamma model is generally used with continuous and 
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non-negative response variables and assumes the constant coefficient of variation that is 
often found in cost data.   
Log transformation can be sometimes used to normalize cost data.  The GLM log 
link model assumes: 
ln(E(y/x)) = Xβ; the relationship of the predictors to the log of the estimated 
criterion mean cost.  
The gamma family of distribution assumes variance, V, is proportional to the 
square of the mean, µ
2
: 
  V(µ) = µ
2
, or V(y/x)proportional to [E(y/x)]
2
, or 
  V[y/x] = α[E(y/x)]λ,  
where α is the shape of the parameter and λ is the specific distribution model (family) 
used in the GLM.   
The λ gives the family distribution: 
  λ = 0 Gaussian 
  λ = 1 Poisson 
  λ = 2  Gamma 
  λ = 3 Inverse Gaussian or Wald 
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 The appropriate use of the gamma model in this study is tested through the 
modified Park’s test for the variance of each cost outcome. (Manning & Mullahy, 2001)    
The modified Park’s test is defined as: 
  ln(Yi – Ŷi) = λ0 + λ1ln(Ŷi) + ei,  
where ln(Yi – Ŷi) is the natural log of the raw residuals squared, ln(Ŷi) is the natural log 
of the predicted Yi, λ0 is a constant and λ1 is the coefficient that gives the family.  
The final GLM gamma log link model can be represented as: 
  ln[E(Yi)] = β0+β1X1+β2X2+ β3X3+…+βkXk; or 
  E(Yi) = exp(β0+β1X1+β2X2+ β3X3+…+βkXk), 
where Yi is the criterion variable, E(Yi) is the expected value of the criterion variable, Xk 
are the predictor variables and βk are the estimated coefficients.  Maximum likelihood 
estimation is used to calculate the parameters (β) of the model.  The appropriate use of 
the log link in this study is assessed through the distribution curves of the raw scale 
variables, their residuals and the log scale variables and residuals. 
3.8.2. Interpretation of the GLM gamma log link model. 
 In a GLM gamma log link model the relationship between the mean of the 
criterion variable (Yi) and the predictor is defined as:  
ln[E(Yi)] = β0+β1X1+β2X2+ β3X3+…+βkXk; or 
  E(Yi) = exp(β0+β1X1+β2X2+ β3X3+…+βkXk); 
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where a change in the criterion variable is considered to be proportional to a change in 
the predictor variable. Interpretations can be described as: 
A 1 unit change in X1 would change the mean of Yi by a factor of exp(β1) or e
β
1 or 
changing X2 from 0 to 1 would change the mean of Yi by a factor of exp(β2) or 
e
β
2. 
The model does not hold the other variables fixed and variable changes adjust for the 
contributions of all other variables in the model.   
In this study,  
 e
β
 >1 when β>0 and indicates increasing cost, 
 e
β
 <1 when β<0 and indicates decreasing cost and, 
 e
β
 =1 when β=0 and indicates no change in cost 
The hypothesis being tested is: 
 H0: e
β
 =1 
 H1: e
β
 ≠1,  
and tested with a Wald chi-squared statistic at α=0.05 level of significance. 
3.9. Study Regression Models. 
 Two types of regression models will be tests: (1) An overall predictive model of 
study variables; and (2) A hierarchical model. 
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1.  Predictive model of study variables:  
1. YTotalcost=β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
2.   YAncillarycost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
3.   YInpatientcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
4.   YOutpatientcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
5.   YPharmacycost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
6.   YProfessionalcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype + 
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e 
2.  A two-step hierarchical regression model will test the effect of community and patient 
enabling variables above and beyond the effect of patient predisposing characteristics and 
need variables. 
Hierarchical entry 1:  Cost ~ length of follow up, age, gender, treatment type, severity. 
Hierarchical entry 2:  Cost ~ length of follow up, age, gender, treatment type, severity, 
cty%belowpoverty, payer type, provider type, pro%belowpoverty.  
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3.10. Study Power and Sample Size. 
In the 4th edition of Using Multivariate Statistics, Tabachnick and Fidell advise to 
attain the best result through the use of the fewest variables (Tabachnick and Fidell, 
2001).  Their list of consideration for variable use include cost, availability, meaning and 
theoretical relationships.  This study primarily relies on theoretical relationships 
identified in prior research to select the variables.  Given the economic perspective of the 
study and the expected small sample size due to the rarity of the disease, the number of 
variables identified for the analysis has been kept to a minimum. 
An online sample size and power calculator was used and a calculated sample size 
of 113 was identified as necessary to provide power of 0.80, assuming an alpha of .05, 
anticipated effect of 0.15 (medium effect, Cohen, 1982). 
 (http://danielsoper.com/statcalc3/calc.aspx?id=1) 
Multivariate regression also requires that the ratio of the number of subjects to 
predictor variable to be substantial enough for the solution to be meaningful.  Again, 
Tabachnick and Fidell provide a simple rule of thumb equation:  N ≥ 50 + 8m, where 
m=the number of independent variables.  In this study the number of independent 
variables, m=9, resulting also in N ≥ 122 and expected power to be > 80% (Tabachnick 
and Fidell, 2001). 
The initial study dataset of identified an overall sample of 837 patients; however, 
due to more limited availability of provider data, the analysis sample reduced to 638.  In 
addition, each cost criterion analysis utilizes only the data, and a corresponding sample 
size, associated with that stated cost.  All sample sizes were reviewed and determined to 
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be greater than the minimum required N ≥ 122; sufficient to meet the requirement for 
>80% power for the analysis. (Table 3.5)   
Table 3.5. Sample Size by Cost Criterion.  
Criterion variable Sample size 
Total 638 
Ancillary 138 
Inpatient 201 
Outpatient 497 
Pharmacy 325 
Professional 618 
 
3.11. Study Sample Flow Charts. 
 The initial sample of 837 eligible patient records from the WHIO data mart is 
described in chapter 3 and is depicted in Figure 3.1.  The sample size available for 
statistical analysis was dependent upon the number of patient records that were present 
within each cost criterion and is subsequently different for each.  Power was assessed for 
all samples and was found to meet the minimum requirement of 80%.  Statistical analysis 
with Generalized Linear Modeling was performed for each cost criterion.  Hierarchical 
modeling of patient and community enabling variables over and above patient 
predisposing and need variables was performed for the total cost criterion only. 
Figures 3.3-3.8 depict the selection flow charts for each cost.  The total cost 
sample (Figure 3.3) loses only those patients where provider data was unavailable and 
includes the largest sample of 638. The professional cost sample of 618 (Figure 3.8), the 
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outpatient cost sample of 497, (Figure 3.6), the pharmacy cost sample of 325 (Figure 3.7) 
and the inpatient cost sample of 201, (Figure3.5) solidly meet the minimum sample size  
power requirements. The ancillary cost sample, (Figure 3.4) has the smallest group of 
138. 
Figure 3.3.Total Cost Sample Flow Chart.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  Patients with patient and provider variable data, 
N=638 
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Figure 3.4.Ancillary Cost Sample Flow Chart. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  patients with patient and provider variable data, 
N=638 
Exclude patients without ancillary cost 
data, N=500 
Ancillary cost sample, N=138 
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Figure 3.5.Inpatient Cost Sample Flow Chart. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  patients with patient and provider variable data, 
N=638 
Exclude patients without inpatient cost 
data, N=437 
Inpatient cost sample, N=201 
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Figure 3.6.Outpatient Cost Sample Flow Chart. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  patients with patient and provider variable data, 
N=638 
Exclude patients without outpatient cost 
data, N=141 
Outpatient cost sample, N=497 
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Figure 3.7.Pharmacy Cost Sample Flow Chart.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  patients with patient and provider variable data, 
N=638 
Exclude patients without pharmacy cost 
data, N=313 
Pharmacy cost sample, N=325 
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Figure 3.8.Professional Cost Sample Flow Chart.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
3.12. Model Selection With Study Data. 
 An assessment of the study data for use with a GLM gamma log link model was 
handled in two ways: (1) Visual inspection of both raw scale and residual scale data for 
use of the log link; and (2) The modified Park’s test to identify the family.  Prior cost 
research was also used to guide the decision of the best choice of model. 
Patients included in WHIO data mart, 4/1/2009-6/30/2011 
N=3,864,345 
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205) 
N=12,504 
Exclude DRG’s other than 200.xx-208.xx 
N=3,851,841 
 
Patients with a diagnosis of acute leukemia  
N=837  
Exclude patients with non-acute diagnosis 
N=11,670 
Exclude patients without county zip code 
data, N=1 
Patients with patient variable data, N=836 
Exclude patients without provider data, 
N=198 
Total cost sample:  patients with patient and provider variable data, 
N=638 
Exclude patients without professional cost 
data, N=20 
Professional cost sample, N=618 
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3.12.1. Distribution of criterion variables. 
Graphical representation of the distribution of each criterion variable, for billed 
cost and standard cost data, are presented in Figures 3.9-3.20. The distribution of the raw 
scale, log raw scale, residual and log residual is provided.  In each of the distributions, the 
raw scale and residual scale distributions indicate non-normal, positively skewed 
distributions that may display high kurtosis.  Each of the variables maintained a 
consistent distribution when comparing billed cost data to standard cost data.  When 
transformed to the log scale, some variables displayed a more normal distribution when 
compare to others; inpatient cost (Figure 3.13-3.14) versus pharmacy cost (Figure 3.17-
3.18).  In general, transformation to the log scale resulted in a closer to normal 
distribution and provides support for the use of the log link method. 
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Figure 3.9. Distribution of Total Billed Cost. 
Distribution of totla billed cost   Distribution of log total billed cost 
 
 
Distribution of total billed cost residual  Distribution of log total billed cost residual 
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Figure 3.10. Distribution of Total Standard Cost. 
 
Distribution of total standard cost  Distribution of log total standard cost 
      
 
 
Distribution of total standard cost residual Distribution of log total standard cost residual  
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Figure 3.11 Distribution of Ancillary Billed Cost. 
 
Distribution of  ancillary billed cost  Distribution of log ancillary billed  cost  
                                  
 
Distribution ancillary billed cost residual Distribution of log ancillary billed cost residual 
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Figure 3.12. Distribution of Ancillary Standard Cost. 
 
Distribution of ancillary standard cost  Distribution of log ancillary standard cost 
 
 
Distribution of ancillary standard cost residual Distribution of log ancillary std cost residual 
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Figure 3.13. Distribution of Inpatient Billed Cost. 
 
Distribution of inpatient billed cost  Distribution of log inpatient billed cost 
 
 
 
Distribution of inpatient billed  cost residual Distribution of log inpatient billed  cost residual 
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Figure 3.14.Distribution of Inpatient Standard Cost. 
 
Distribution of inpatient standard cost  Distribution of log inpatient standard cost 
 
 
Distribution of inpatient standard cost residual Distribution of log inpatient std cost residual 
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Figure 3.15. Distribution of Outpatient Billed Cost. 
 
Distribution of outpatient billed cost      Distribution of log outpatient billed  cost 
 
 
Distribution of outpatient billed cost residual Distribution of log outpatient billed cost residual 
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Figure 3.16. Distribution of Outpatient Standard Cost. 
 
Distribution of outpatient standard cost        Distribution of log outpatient standard cost 
 
 
Distribution of outpatient cost std residual       Distribution of log outpatient std cost residual 
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Figure 3.17. Distribution of Pharmacy Billed Cost. 
 
Distribution of  pharmacy billed cost  Distribution of log pharmacy billed cost 
 
 
 
Distribution of pharmacy billed cost residual Distribution of log pharmacy billed cost residual 
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Figure 3.18. Distribution of Pharmacy Standard Cost. 
 
Distribution of pharmacy standard cost  Distribution of log pharmacy standard cost 
 
 
 
Distribution of pharmacy std cost residual Distribution of log pharmacy std cost residual 
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Figure 3.19. Distribution of Professional Billed Cost. 
 
Distribution of professional billed cost  Distribution of log professional billed cost 
 
 
Distribution of professional billed cost residual Distribution of log professional billed residual 
 
 
 
 
 
 
 
 
 
 
 
68 
 
 
 
Figure 3.20. Distribution of Professional Standard Cost. 
 
Distribution of professional standard cost Distribution of log professional standard cost 
 
 
 
Distribution of professional std cost residual Distribution of log professional std cost residual 
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3.12.2. Results of the Modified Park’s Test for Family Distribution of 
Criterion Variables.  
 Results from the modified Park’s test to determine the family distribution of the 
criterion variables are presented in Table 3.6.  The test results were somewhat 
inconclusive, with a λ ranging between 1.2 for standard outpatient cost and 2.0 for billed 
ancillary cost.  With these results either a gamma distribution or a Poisson distribution 
would seem to be the most appropriate choice.  Prior health economics research 
consistently selects the gamma family as the choice for cost data distributions.  Given the 
range of results and relying on the prior studies, this study will use the gamma family 
model. 
 Table 3.6. Results of Modified Park’s Test. 
Cost Outcome  λ s.e. 95% CI p-value 
 
Total cost      
 Billed  1.5  0.0698 1.3 – 1.6 <0.0001 
 Standard 1.4 0.0694 1.3 – 1.6 <0.0001 
 
Inpatient cost      
 Billed 1.3 0.2044 0.9 – 1.7 <0.0001 
 Standard 1.3 0.8251 0.8 – 1.8 <0.0001 
 
Outpatient cost      
 Billed 1.4 0.1087 1.2 – 1.6 <0.0001 
 Standard 1.2 0.1001 0.9 – 1.3 <0.0001 
 
Ancillary cost      
 Billed 2.0 0.2707 1.5 – 2.5 <0.0001 
 Standard 1.9 0.2326 1.5 – 2.4 <0.0001 
 
Professional cost      
 Billed 1.3 0.0869 1.1 – 1.5 <0.0001 
 Standard 1.6 0.1056 1.4 – 1.8 <0.0001 
 
Pharmacy cost      
 Billed 1.3 0.1399 1.0 – 1.6 <0.0001 
 Standard 1.8 0.1653 1.4 – 2.1 <0.0001 
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3.13. Protection of Human Participants and the Health Insurance Portability and 
Accountability Act 
In accordance with the Health Insurance Portability and Accountability Act 
(HIPPA) requirements, all patient identifiers were removed prior to receipt of study data.   
According to Public Health Information regulations this is considered a limited data set 
because of the presence of ZIP code data. 
The University of Wisconsin-Milwaukee Institutional Review Board granted 
Exempt Status under Category 4 as governed by 45 CFR 46.101 on April 13, 2012.  
Appendix F contains a copy of the New Study-Notice of IRB Exempt Status letter. 
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CHAPTER 4:  Results 
 Results of the data analyses presented in this chapter are separated into three 
sections: (1) Descriptive statistics of the analysis variables for cost criterions; (2) Results 
of the predictive model by cost criterion and cost type; and (3) Results of the hierarchical 
model of patient and community enabling resources over patient predisposing 
characteristics and need for services. 
4.1. Descriptive Statistics of Analysis Variables. 
 Predictor variable characteristics are presented for each criterion in Tables 4.1-
4.6: Total cost (Table 4.1); Ancillary cost (Table 4.2); Inpatient cost (Table 4.3); 
Outpatient cost (Table 4.4); Pharmacy cost (Table 4.5); and Professional cost (Table 4.6). 
Descriptive statistics of each criterion variable are presented for the billed cost (Table 
4.7) and the standard cost (Table 4.8).   
4.1.1. Descriptive statistics of predictor variables   
 In the WHIO datamart, patient claims are associated with type of services 
rendered.  A patient may not have used all service types within the 24 month timeframe 
of this study causing the sample sizes between the six cost criterions to vary as seen in 
the chapter 3 flow charts.  Predictor variable descriptive statistics show similarities 
between the samples for age, gender, patient % under poverty, payer type and provider % 
under poverty but do show some differences in the percentages of: (1) Treatment type, 
where there was a slightly higher percentage of treatment with HCT in ancillary cost and 
inpatient cost (11-12% versus 3-6% respectively); (2) Levels of severity, where total cost 
and professional cost had a low to medium/low range of severity; inpatient cost, 
outpatient cost and pharmacy cost showed higher levels of severity in the low/medium to 
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high/medium range and; ancillary costs showed medium/high to high levels of severity 
and; (3) The mean length of follow up for patients ranged from a low of 330 days in the 
total cost to a high of 445 days in the pharmacy cost and may be attributed to the 
differences in the sample size as well as differences in the complexity of the total cost 
claim (comprised of many types of services) versus the single services of the other costs.  
4.1.1.1. Total cost.  
The predictor variables descriptive characteristics of total cost are presented in 
Table 4.1.  This sample contained 837 patients but was reduced to 638 patients due to the 
limited amount of provider data.  Mean age was 27 years with a range of 0-90 with 
slightly more males (56%) present.  Mean length of follow up in the datamart was 330 
days with a range from 0-729.  The mean of the patient socioeconomic measure county % 
under poverty is 12.36 and ranged from 4.6% – 26%.   Most patients were treated with 
chemotherapy only (97%) and had a severity score that was either low or medium/low 
(64%).  Payer types were fairly evenly distributed; 48% commercial versus 52% public.  
Community providers exclusively treated 49% of patients, 27% were treated at least once 
at an academic medical center and 24% of the providers were undetermined.  The mean 
of the provider socioeconomic variable % under poverty was 6.35% and ranged from 
0.5% - 39.6%. 
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Table 4.1. Descriptive Statistics of Predictor Variables for Total Cost.  
Predisposing characteristic  
Age, n 837 
     Mean ± s.d. 27 ± 23.64 
     Median 17.0 
     Range 0-90 
 
Gender, n (%) 837 
     Female 367 (44) 
     Male 470 (56) 
 
Length of follow up, n 837 
     Mean ± s.d. 330 ± 265 
     Median 363 
 
Need  
 
Treatment type, n (%) 837 
     Chemotherapy only 810 (97) 
     Chemotherapy and HCT 27 ( 3) 
 
Severity, n (%) 837 
     Low 95 (11) 
     Low/medium 445 (53) 
     High/medium 152 (18) 
     High 145 (17) 
  
Enabling resources   
Patient county zip code % under poverty, 
n 
837 
     Mean ± s.d 12.36 ± 4.47 
     Median 12.2 
     Range 4.6 – 26.0 
 
Payer type, n (%) 
 
837 
     Commercial 400 (48) 
     Public 437 (52) 
 
Provider type, n (%) 837  
     Community 410 (49) 
     Academic medical center 228 (27) 
     Not determined 199 (24) 
 
Provider zip code % under poverty, n  638 
     Mean ± s.d. 6.35 ± 5.9 
     Median 3.3 
     Range 0.5-39.6 
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4.1.1.2. Ancillary cost. 
The predictor variables descriptive characteristics of ancillary cost are presented 
in Table 4.2.  This sample contained 164 patients but was reduced to 138 patients due to 
the limited amount of provider data.  Mean age is 28 years with a range of 0-88 and more 
males (62%) were present.  Mean length of follow up in the datamart was 439 days with a 
range from 0-729.  The mean of the patient socioeconomic measure county % under 
poverty is 12.43% with a range of 4.6% – 20.1%.   Most patients were treated with 
chemotherapy only (88%) and this sample had the highest severity scores of either 
medium/high or high (61% combined).  The majority of payer types are public (56%).  
Community providers exclusively treated 45% of patients, 39% were treated at least once 
at an academic medical center and 16% of the providers were undetermined.  The mean 
of the provider socioeconomic variable % under poverty was 5.97% and ranged from 
1.10% - 39.6%. 
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Table 4.2. Descriptive Statistics of Predictor Variables for Ancillary Cost. 
Predisposing characteristics  
Age, n 164 
     Mean ± s.d. 28 ± 25 
     Median 17 
     Range 0 – 88 
 
Gender, n (%) 164 
     Female 62 (38) 
     Male 102 (62) 
 
Length of follow up, days, n 164 
     Mean ± s.d. 439 ± 235 
     Median 461 
     Range 0 – 729 
 
Need   
Treatment type, n (%) 164 
     Chemotherapy only 145 (88) 
     Chemotherapy and HCT 19 (12) 
 
Severity, n (%) 164 
     Low 10 (  6) 
     Low/medium 53 (33) 
     High/medium 40 (24) 
     High 61 (37) 
  
Enabling resources  
Patient county zip code % under poverty, 
n 
164 
     Mean ± s.d 12.43 ± 4.44 
     Median 12.20 
     Range 4.60 – 20.10 
  
Payer type, n (%) 164 
     Commercial 72 (44) 
     Public 92 (56) 
 
Provider type, n (%) 164 
     Community 74 (45) 
     Academic medical center 64 (39) 
     Not determined 26 (16) 
 
Provider zip code % under poverty, n  138  
     Mean ± s.d. 5.97 ± 5.39 
     Median 3.55 
     Range 1.10 – 39.60 
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4.1.1.3. Inpatient cost.  
The predictor variables descriptive characteristics of inpatient cost are presented 
in Table 4.3.  This sample contained 232 patients but was reduced to 201 patients due to 
the limited amount of provider data.  Mean age is 27 years with a range of 0-90 and a 
higher percentage of males (66%) are present.  Mean length of follow up in the datamart 
was 420 days with a range from 0-729.  The mean of the patient socioeconomic measure 
county % under poverty is 11.98 and had a range of 4.6% – 20.1%.   Most patients were 
treated with chemotherapy only (89%) and had severity scores of either medium/low or 
medium/high (63% combined).  The majority of payer types were public (56%).  
Community providers exclusively treated 48% of patients, 39% were treated at least once 
at an academic medical center and 13% of the providers were undetermined.  The mean 
of the provider socioeconomic variable % under poverty was 6.10% and ranged from 
1.2% - 39.6%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
Table 4.3. Descriptive Statistics of Predictor Variables for Inpatient Cost. 
 
Predisposing characteristics  
Age, n 232 
     Mean ± s.d. 27 ± 25 
     Median 16 
     Range 0 – 90 
  
Gender, n (%) 232 
     Female 79 (34) 
     Male 153 (66) 
  
Length of follow up, days, n 232 
     Mean ± s.d. 420 ± 243  
     Median 449 
     Range 0 - 729 
  
Need   
Treatment type, n (%) 232 
     Chemotherapy only 206 (89) 
     Chemotherapy and HCT 26 (11) 
 
Severity, n (%) 
 
232 
     Low 19 (12) 
     Low/medium 92 (39) 
     High/medium 60 (24) 
     High 61 (25) 
  
Enabling resources  
Patient county zip code % under poverty, 
n 
232 
     Mean ± s.d 11.98 ± 4.19 
     Median 12.2 
     Range 4.60 – 20.10 
  
Payer type, n (%) 232 
     Commercial 102 (44) 
     Public 130 (56) 
  
Provider type, n (%) 232 
     Community 111 (48) 
     Academic medical center 90 (39) 
     Not determined 31 (13) 
  
Provider zip code % under poverty, n  201 
     Mean ± s.d. 6.10 ± 5.61 
     Median 3.20 
     Range 1.20 – 39.60 
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4.1.1.4 Outpatient cost. 
 
The predictor variables descriptive characteristics of outpatient cost are presented 
in Table 4.4.  This sample contains 639 patients but is reduced to 497 patients due to the 
limited amount of provider data.  Mean age is 27 years with a range of 0-90 and with 
more males (57%) present.  Mean length of follow up in the datamart was 388 days with 
a range from 0-729.  The mean of the patient socioeconomic measure county % under 
poverty is 12.23% with a range of 4.6% – 21.1%.   Most patients were treated with 
chemotherapy only (96%) and severity scores ranged from medium/low or medium/high 
(74% combined).  The majority of payer types were public (52%).  Community providers 
exclusively treated 47% of patients, 30% were treated at least once at an academic 
medical center and 23% of the providers were undetermined.  The mean of the provider 
socioeconomic variable % under poverty was 6.41% and ranged from 0.5% - 39.6%. 
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Table 4.4. Descriptive Statistics of Predictor Variables for Outpatient Cost. 
 
Predisposing characteristics  
Age, years, n 639 
     Mean ± s.d. 27 ± 24 
     Median 17 
     Range 0 - 90 
  
Gender, n (%) 639 
     Female 274 (43) 
     Male 365 (57) 
 
Length of follow up, days, n 
 
639 
     Mean ± s.d. 388 ± 252 
     Median 413 
     Range 0 – 729 
  
Need   
Treatment type, n (%) 639 
     Chemotherapy only 612 (96) 
     Chemotherapy and HCT 27 ( 4) 
  
Severity, n (%) 639 
     Low 71 (11) 
     Low/medium 338 (53) 
     High/medium 131 (21) 
     High 99 (15) 
  
Enabling resources  
Patient county zip code % under poverty, 
n 
639 
     Mean ± s.d 12.23 ± 4.47 
     Median 12.20 
     Range 
 
4.60 – 21.10 
Payer type, n (%) 639 
    Commercial 309 (48) 
     Public 330 (52) 
 
Provider type, n (%) 639 
     Community 303 (47) 
     Academic medical center 194 (30) 
     Not determined 142 (23) 
 
Provider zip code % under poverty, n  497 
     Mean ± s.d. 6.41 ± 5.95 
     Median 3.20 
     Range 0.50 – 39.60 
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4.1.1.5. Pharmacy cost.  
 
The predictor variables descriptive characteristics of pharmacy cost are presented 
in Table 4.5.  This sample contains 390 patients but is reduced to 325 patients due to the 
limited amount of provider data.  Mean age is 27 years with a range of 0-90 and has 
slightly more males (59%) present.  Mean length of follow up in the datamart was 445 
days with a range from 0-729.  The mean of the patient socioeconomic measure county % 
under poverty of 12.4% and had a range of 4.6% – 20.1%.   Most patients were treated 
with chemotherapy only (94%) with slightly higher severity scores of either medium/low 
or medium/high (69% combined).  The majority of payer types were public (56%).  
Community providers exclusively treated 47% of patients were treated, 36% were treated 
at least once at an academic medical center and 17% of the providers were undetermined.  
The mean of the provider socioeconomic variable % under poverty was 6.7% and ranged 
from 1.1% - 39.6%. 
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Table 4.5 Descriptive Statistics of Predictor Variables for Pharmacy Cost 
 
Predisposing characteristics  
Age, years, n 390 
     Mean ± s.d. 27 ± 25 
     Median 16 
     Range 0 – 90 
 
Gender, n (%) 390 
     Female 158 (41) 
     Male 232 (59) 
  
Length of follow up, days, n 390 
     Mean ± s.d. 445 ± 240 
     Median 488 
     Range 0 – 729 
  
Need   
Treatment type, n (%) 390 
    Chemotherapy only 365 (94) 
    Chemotherapy and HCT 25 (  6) 
  
Severity, n (%) 390 
     Low 38 (10) 
     Low/medium 185 (47) 
     High/medium 84 (22) 
     High 83 (21) 
  
Enabling resources  
Patient county zip code % under poverty, 
n 
390 
     Mean ± s.d 12.40 ± 4.28 
     Median 12.20 
     Range 4.60 – 20.10 
 
Payer type, n (%) 390 
     Commercial 173 (44) 
     Public 217 (56) 
 
Provider type, n (%) 390 
     Community 185 (47) 
     Academic medical center 140 (36) 
     Not determined 65 (17) 
 
Provider zip code % under poverty, n  325 
     Mean ± s.d. 6.70 ± 5,73 
     Median 4.30 
     Range 1.10 – 39.60 
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4.1.1.6. Professional cost.  
The predictor variables descriptive characteristics of professional cost are 
presented in Table 4.6.  This sample contains 748 patients but is reduced to 618 patients 
due to the limited amount of available provider data.  Mean age is 27 years with a range 
of 0-90 with slightly more males (56%) present.  Mean length of follow up in the 
datamart was 350 days with a range from 0-729.  The mean of the patient socioeconomic 
measure county % under poverty is 12.41% with a range of 4.6% - 26%.   Most patients 
were treated with chemotherapy only (97%) and had a severity score ranging from low to 
low/medium (65% combined).  The majority of payer types were public (53%).  
Community providers exclusively treated 52% of all patients, 31% were treated at least 
once at an academic medical center and 17% of the providers were undetermined.  The 
mean of the provider socioeconomic variable % under poverty was 6.4% and ranged from 
0.5% - 39.6%. 
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Table 4.6. Descriptive Statistics of Predictor Variables for Professional Cost. 
 
Predisposing characteristics  
Age, years, n 748 
     Mean ± s.d. 27 ± 23 
     Median 17 
     Range 0 – 90 
 
Gender, n (%) 748 
     Female 329 (44) 
     Male 419 (56) 
 
Length of follow up, days, n 748 
     Mean ± s.d. 354 ± 261 
     Median 375 
     Range 0 – 729 
  
Need   
Treatment type, n (%) 748 
     Chemotherapy only 722 (97) 
     Chemotherapy and HCT 26 (  3) 
  
Severity, n (%) 748 
     Low 84 (11) 
     Low/medium 405 (54) 
     High/medium 138 (18) 
     High 121 (16) 
  
Enabling resources  
Patient county zip code % under poverty, 
n 
747 
     Mean ± s.d 12.41 ± 4.55 
     Median 12.20 
     Range 4.60 – 26.00 
 
Payer type, n (%) 748 
     Commercial 352 (47) 
     Public 396 (53) 
 
Provider type, n (%) 748 
     Community 390 (52) 
     Academic medical center 228 (31) 
     Not determined 130 (17) 
 
Provider zip code % under poverty, n  618 
     Mean ± s.d. 6.44 ± 5.98 
     Median 3.60 
     Range 0.50 – 39.60 
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4.1.2. Descriptive statistics of criterion variables. 
 This study uses six cost criterion variables: (1) Total cost; (2) 
Ancillary cost; (3) Inpatient cost; (4) Outpatient cost; (5) Pharmacy cost; and (6) 
Professional cost.  Each cost criterion is analyzed by both billed cost, presented in Table 
4.7 and standard cost, presented in Table 4.8.    
4.1.2.1. Billed cost. 
 Billed cost criterion descriptive statistics are presented in Table 4.7.  Mean billed 
costs varied greatly between criterion variables with inpatient cost having the  highest 
mean cost of $15435 ± $221,790 with range $790-$1,671,326, followed by total cost 
mean $86,309 ± $206,913 with range of $29-$1,866,606, the pharmacy cost mean 
$25,108 ± $80,850 with range $1-$1,447,914, the outpatient cost mean $21,424 ± 
$43,720 with range $29-$571,594, the professional cost mean $16,077 ± $80,85 with 
range $38-$203,272 and the ancillary cost mean $4,101 ± $8,475 with range $7-$63,360.   
The median and quartile range of the data additionally provides useful distribution 
measures of each criterion variable and indicate the presence of extreme values at both 
low and high data points.  There were large differences in value between the medians and 
the means however, the medians showed a similar trend when comparing between the 
criterion variables with an inpatient median cost $71,277 with quartile range $2,116-
$187,595, a median total cost $6,034 with quartile range $1,198-$66,093, a median 
pharmacy cost $6,716 with quartile range $647-$26,652, a median outpatient cost $4,972 
with quartile range $1,280-$23,915, a median professional  cost $2,451 with quartile 
range of $676-$17,748 and a median ancillary cost $1,262 with quartile range $373-
$3,878.   
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Table 4.7. Descriptive Statistics for Billed Cost. 
Criterion 
variable 
($) 
 
 
Mean 
 
Median 
 
S.D. 
 
Range 
 
25% 
quartile 
 
75% 
quartile 
Total cost 86,309 6,034 206,913 29 - 1,866,606 1,198 66,093 
Ancillary 
cost 
 
4,101 1,262 8,475 7 – 63,360 373 3,878 
Inpatient 
cost 
 
155,435 71,377 221,790 790 – 1,671,326 26,116 187,595 
Outpatient 
cost 
 
21,424 4,972 43,720 29 – 571,594 1,280 23,915 
Pharmacy 
cost 
 
25,108 6,716 80,850 1 – 1,447,914 647 26,652 
Professional 
cost 
16,077 2,451 80,850 38 – 203,272 676 17,748 
 
4.1.2.2. Standard cost. 
 The descriptive statistics of standard cost is presented in Table 4.8.  The standard 
costs are consistently lower in value for all criterion variables when compared to billed 
cost. Taking the lower value into account, the standard costs follow the same general 
trend as the billed cost with a high mean, large standard deviation and wide range of data.  
The inpatient cost has the highest mean cost $80,786 ± $104,001 with range $2,680-
$836,656, followed by the total cost mean $43,379 ± $102,703 with range $10-
$1,229,960 , the pharmacy cost mean $17,078 ± $60,011 with range $1-$1,097,438, the 
outpatient cost of $8,410 ± $17,589 with range $10-$227,957, the professional cost mean 
$6,490 ± 11,378 with range $7-$80,867 and, the ancillary cost mean $4,123 ± 8,833 with 
range $5-$64,248.  The median, combined with the 25%-75% quartile range provide a 
more comprehensive description of the data.  Inpatient cost has the highest median cost 
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$40,908 and a 25%-75% quartile range $16,855 - $108,750, followed by the median 
pharmacy cost $5,070 with a 25% - 75% quartile range $483 - $17,434, the median total 
cost  $2,723 with a 25% - 75% quartile range $539 - $35,471, the median outpatient cost 
$1,953 with a 25% - 75% quartile range $493 - $9,208, the median ancillary cost $1,230 
with a 25% - 75% quartile range $296 - $3,248 and, the median  professional cost $1,002 
with a 25% - 75% quartile range $298 to $7448.  The professional cost had the greatest 
reduction in value because of the standardization of cost and resulted in the lowest 
median cost.  Standard ancillary cost moved from the lowest median in the billed cost to 
the second lowest median in the standard cost.   All other costs remained in the same high 
to low position. 
Table 4.8. Descriptive Statistics for Standard Cost. 
Criterion 
variable 
($) 
 
 
Mean 
 
Median 
 
S.D. 
 
Range 
 
25% 
quartile 
 
75% 
quartile 
Total cost 43,379 2,723 102,703 10 – 1,228,960 539 35,471 
Ancillary 
cost 
 
4,123 1,230 8,834 5 – 64,248 296 3,248 
Inpatient 
cost 
 
80,787 40,908 104,001 2,680 – 836,656 16,855 107,750 
Outpatient 
cost 
8,410 1,953 17,590 10 – 227,957 493 9208 
Pharmacy 
cost 
 
17,078 5,070 60,012 1 – 1,097,437 483 17,434 
Professional 
cost 
6,491 1,002 11,379 7 – 80,867 298 7,448 
 
4.2. Results of the Predictors of Cost Model. 
 Multivariate methods were used to model the cost criterion variables related to: 
(1) Whether a patients predisposing characteristics (i.e., age, gender and length of follow 
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up), their need for service factors (i.e., treatment type and episode severity) and the 
patient and community enabling resources (i.e., patient county of residence % under 
poverty, payer type, provider type and its location % under poverty) are predictive of 
cost; and (2) An examination of the magnitude of predictor variable influence on cost 
criterion variables. The underlying hypothesis is each predictor variable will have a 
significant effect on the cost criterion with varying degrees of magnitude.  Generalized 
linear model (GLM) gamma log link models were run for each cost criterion and each 
cost type, billed and standard.  Significance is assessed at the p ≤ 0.05 level. 
Analysis results of the full and reduced models are presented by cost criterion and 
cost type. The exponential conditional mean is reported as the e
β 
coefficient and 
represents the proportional change factor; a one unit change in the predictor variable will 
result in a proportional change of e
β 
in the criterion variable.  The full model included all 
predictor variables and was run separately for total billed cost and total standard cost.    
Reduced model variables were identified in the GLM through a Type 3 analysis which 
used a chi-square test of the likelihood ratio with, α=0.05.  A second GLM analysis was 
run using only the variables that tested as significant.  Results for both the full model and 
reduced model variables are presented. 
4.2.1. Total cost.   
The estimated results for the total cost are presented in Table 4.9.  The full model 
predictor  variable estimates  resulting in a significant increase to total cost included:  (1) 
Gender, where male gender is 1.69 times total billed cost of female gender ([CI=1.29-
2.2], p<.0001) and a 1.59 times total standard cost of female gender ([CI=1.22-2.09], 
p=.0007) and; (2) Length of follow up, where a per day increase in length of follow up is 
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1.001 times the total billed cost ([CI=1.001-1.002], p<.0001) and with the same result in 
total standard cost. 
The significant variable estimates that resulted in a reduction to the cost criterion 
variables included; (1) Treatment type, where the cost of chemotherapy only treatment is 
0.12 times the cost of chemotherapy and HCT treatment ([CI=0.06-0.22], p<.0001); (2) 
Severity level, where cost for lower levels of severity resulted in a reduction in cost when 
compared to higher levels of severity.  Severity level 1, low level, was 0.36 times the cost 
of severity level 4, high level, ([CI=0.21-0.006), p<.0001) for total billed cost and 0.35 
times the cost of severity level 4 for total standard cost ([CI=0.21-0.59], p<.0001) and, 
severity level 2, medium/low severity, was 0.39 times the cost of severity level 4 in total 
billed cost ([CI=0.27- 1.08], p=<.0001) and 0.41 times the cost of severity level 4 in total 
standard cost ([CI=0.28-0.6], p<.0001; (3) Age, where a one year increase in age was 
0.99 times the cost of the prior year in total billed cost, ([CI=0.98-0.99], p=0.0002) and 
was similar, 0.99 times, in total standard cost, ([CI=0.99-0.99], p=0.002) and; (4) 
Provider type, where the cost of claims from a community provider was 0.77 times the 
cost of claims from an academic provider in total billed cost ([CI=0.51-0.89], p=0.007) 
and 0.67 times the cost from an academic provider in total standard cost ([CI=0.5-0.88], 
p=0.006). 
Variable estimate results not significant in the models include:  (1) Patient county 
% under poverty, where a 1% increase in the percentage under poverty rate was 0.99 
times total billed cost when compared to lower % under poverty ([CI=0.97-1.02], p=0.79) 
with a similar result in total standard cost, 0.99, ([CI=0.97-1.22], p=0.77); (2). Payer 
type, where a commercial payer was 0.77 times the cost of a public payer in total billed 
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cost ([CI=0.59-1.02], p=0.06) and .79 times the cost of a public payer in total standard 
cost ([0.59-1.04], p=0.1); (3) Severity level 3, was 0.96 times the cost of severity level 4 
in total billed cost ([CI=0.47-1.08], p=0.12) and 0.77 times the cost of severity level 4 in 
total standard cost ([CI=0.5-1.18], p=0.24) and; (4) Provider % under poverty where a 
1% increase in the % under poverty rate was 0.99 times the total billed cost of the lower 
poverty  rate ([CI=0.98-1.02], p=0.65) and 0.99 times the total standard cost of the lower 
poverty rate ([CI=0.97-1.16], p=0.49). 
In the reduced model, severity level 3 and 4 were combined. The variable 
estimates that resulted in a significant increase to the cost criterion variables include: (1) 
Gender, where the cost of total billed for males was 1.75 times the cost of females 
([CI=1.36-2.27], p=<0.0001), and 1.66 times the cost of females in total standard 
([CI=1.28-2.15], p=0.0001); and (2) Length of follow up, where a one day increase in the 
length of follow up was 1.001 times the cost of the shorter timeframe in total billed cost 
and total standard cost, ([CI=0.001-0.002, p<0.0001).  
Costs were significantly reduced by: (1) Treatment type, where chemotherapy 
only cost was 0.13 times the cost of chemotherapy and HCT in total billed cost 
([CI=0.06-0.23, p<0.0001) and 0.14 times the cost of chemotherapy and HCT in total 
standard cost ([CI=0.06-0.26], p<0.0001); (2) Severity level, where severity level 1 was 
0.44 times the cost of severity levels 3 and 4 in total billed cost, ([CI=0.28-0.7], 
p=0.0003) and 0.41 times the cost of severity levels 3 and 4 in total standard cost, 
([CI=0.26-0.61], p=0.0002) and severity level 2 was 0.44 times the cost of severity levels 
3 and 4 in total billed cost ([CI=0.33-0.58], p<0.0001), and 0.45 times the cost of severity 
levels 3 and 4 in total standard cost ([CI=0.34-0.61], p<0.0001); (3) Community 
90 
 
 
 
providers resulted in 0.73 times the cost of academic providers in total billed cost 
([CI=0.57-0.96], p=0.02), and 0.71 times the cost of academic providers in total standard 
cost ([CI=0.54-0.94], p=0.01); and (4) A per year increase in age had 0.98 times the cost 
of the prior year in total billed cost ([CI=0.98-0.99], p<0.0001) and 0.99 times the cost of 
the prior year in total standard cost (CI=0.98-0.99], p=0.0007). 
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Table 4.9. Estimated Results for Total Cost.  
 
 
1Results in bold are significant in the model 
2Severity level 3 and 4 are combined 
*Significant at α=.05 
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4.2.2. Ancillary cost.  
The estimated results for the ancillary cost are presented in Table 4.10.  In the full 
model, there were no significant variable estimates which resulted in an increase to the 
cost criterion variable.   
 Variable estimates which significantly reduced cost included: (1) Level of 
severity resulted in the largest cost decrease where, severity level 1 cost was 0.23 times 
the cost of severity level 4 in ancillary billed cost ([CI=0.07-0.93), p=0.02), and 0.23 
times the cost of severity level 4 in ancillary standard cost ([CI=.06-.97], p=0.03.  
Severity level 2 was 0.32 times the cost of severity level 4 in ancillary billed cost 
([CI=0.16-0.60], p=0.0005), and 0.27 times the cost of severity level 4 in ancillary 
standard cost ([CI=0.13-0.52], p=0.0001).  Severity level 3 was 0.30 times the cost of 
severity level 4 in ancillary billed cost ([CI=0.16-0.57], p=0.0002) and 0.25 times the 
cost of severity level 4 in ancillary standard cost ([CI=0.16-0.57], p=0.0002).  All 
severity levels were significant in the model but exhibited wide confidence intervals 
making the estimate unreliable; (2) Provider type, where community providers ancillary 
billed costs were 0.50 times the cost of academic providers ancillary billed cost, 
([CI=0.29-0.87], p=0.02) and 0.48 times the cost of academic providers ancillary 
standard cost, ([0.27-0.84], p=0.01); and (3) Age, where a per year increase in age 
resulted in 0.98 times ancillary billed cost, ([CI=0.97-0.99], p=0.01) and with the same 
result for ancillary standard cost. 
 Variable estimates that increased ancillary cost but were not significant in the 
model include:  (1) Payer type, where commercial payers were estimated as 1.60 times 
the ancillary billed cost of public payers ([CI=.97-2.66], p=.06), and 1.21 times the 
93 
 
 
 
ancillary standard cost of public payers ([CI=0.73-2.10], p=0.45); and (2) Patient county 
% under poverty estimated 1.01 times ancillary billed cost per percentage increase in the 
rate under poverty ([CI=0.96-1.06], p=0.66) and was 1.007 times ancillary standard cost 
([CI=0.96-1.06], p=0.77). Variable estimates that reduced cost but were not significant in 
the full model are: (1) Treatment type, where chemotherapy only treatment cost was 0.51 
times the cost of chemotherapy and HCT in the ancillary billed cost ([CI=0.23-1.02], 
p=0.07), and 0.54 times the cost of chemotherapy and HCT in the ancillary standard cost 
([CI=0.25-1.07], p=0.10); (2) Gender, where cost for males was 0.85 times the cost for 
females in ancillary billed cost, ([CI=0.50-1.44], p=0.57) and cost for males was 0.83 
times the cost for females in ancillary standard cost, ([CI=0.47-1.43], p=0.52); (3) 
Provider % under poverty, where with a 1% increase in the % under poverty ancillary 
billed cost was 0.96 of the lower % under poverty, ([CI=0.92-1.01], p=0.08) and ancillary 
standard cost was the same; and (4) Length of follow up, where with every 1 day increase 
in ancillary billed cost was 0.99 times the prior day, ([0.97-0.99], p=0.58) and ancillary 
standard cost was 0.99 times the prior day, ([0.97-1.00], p=0.72).  
 Three variable estimates entered the reduced model; age, severity and provider 
type.  Two of these variables significantly resulted in a cost reduction in the model:  (1) 
Severity levels had the largest effect where severity level 1 was 0.29 times the ancillary 
billed cost of severity level 4 ([CI=0.10-1.01], p=0.05), and 0.24 times the ancillary 
standard cost of severity level 4 ([CI=0.07-0.95], p=0.02), severity level 2 was 0.44 times 
the ancillary billed cost of severity level 4 ([CI=0.24-0.81], p=0.008) and 0.34 times the 
ancillary standard cost of severity level 4 ([CI=0.19-0.66], p=0.001) and severity level 3 
was 0.42 times the ancillary billed cost of severity level 4 ([CI=0.22-0.81], p=0.008) and 
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was 0.32 times the ancillary standard cost of severity level 4 (CI=0.17-0.61], p=0.0004); 
and (2) Commercial providers had 0.45 times the ancillary billed cost of public providers 
([CI=0.26-0.75], p=0.002) and 0.46 times the ancillary standard cost of public providers 
([CI=0.26-0.79], p=0.005).  Age was not significant in the reduced model.   
 
Table 4.10. Estimated Results for Ancillary Cost.  
 
 
 
 
1Results in bold are significant in the model 
*Significant at α=.05 
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4.2.3. Inpatient cost.  
The estimated result for inpatient costs are presented in Table 4.11.  In the full 
model only gender, for billed cost only, significantly estimated an increase in the cost 
criterion variable with male gender 1.4 times the inpatient billed cost compared to female 
gender, ([CI=1.04-1.91], p=0.03.  
 Variable estimates that significantly reduced inpatient costs are:  (1) Treatment 
type, where chemotherapy only treatment is 0.25 times the inpatient billed cost of 
treatment with both chemotherapy and HCT, ([CI=0.16-0.39], p<0.0001) and 0.28 times 
the cost of inpatient standard cost of treatment with chemotherapy and HCT, ([CI=0.18-
0.41], p<.0001); (2) Severity level, where Level 1 severity is 0.29 times the cost of level 
4 severity of inpatient billed cost ([CI=0.17-0.53], p<.0001) and 0.26 times the cost of 
level 4 severity of inpatient standard cost ([CI=0.18-0.53], p<.0001) and Level 2 severity 
is 0.54 times the cost of level 4 severity of inpatient billed cost ([CI=0.38-0.78], p=0.001) 
and 0.59 times the costs of level 4 severity of inpatient standard cost ([CI=0.42-0.83], 
p=0.002); (3) Provider type, where costs of a community provider are 0.69 times the 
inpatient billed costs of an academic provider, ([CI=0.5-0.94], p=0.02) and 0.71 times the 
inpatient standard costs of an academic provider ([CI=0.53-0.94], p=0.02); (4) Age, a per 
year increase in age resulted in 0.98 times the inpatient billed cost, ([CI=0.98-0.99], 
p<.0001) and had the same result for inpatient standard cost; and (5) Length of follow up, 
where the per day increase in length of follow up was 0.99 times inpatient billed cost, 
([CI=0.99-0.99], p=0.03) and 0.99 times inpatient standard cost ([CI=0.99-1], p=0.02). 
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Variable estimates that were not significant in the model include:  (1) Gender 
where the standard cost of males is 1.22 times the inpatient standard cost compared to 
female gender, ([CI=0.93-1.61], p=0.15); (2) Payer type where a commercial payer is 
0.86 times inpatient billed cost of a public payer, ([CI=0.64-1.17], p=0.35) and 0.86 times 
inpatient standard cost of a public payer, ([CI=0.65-1.15], p=0.33) but is not significant 
in both models; (3) Severity level 3 is 1.06 times the cost of level 4 severity in inpatient 
billed cost, ([CI=0.72-1.55], p=0.75), and 1.18 times the cost of level 4 severity in 
inpatient standard cost, ([CI=0.84-1.66], p=0.33); (4) Patient county % under poverty 
where a percentile increase in the rate of county poverty is 1.01 times the inpatient billed 
cost, ([CI=0.98-1.05], p=0.35) and is 1.01 times the cost of the inpatient standard cost, 
([CI=0.99-1.04], p=0.32); and (5) Provider % under poverty where a 1% increase in the 
rate of provider % under poverty is 0.99 times inpatient billed cost, ([CI=0.97-1.02], 
p=0.89), and the same for inpatient standard cost. 
 In the reduced model, billed cost gender is the only variable estimate that 
increased the cost criterion variables, where male gender was 1.41 times the cost of 
female gender of inpatient billed cost, ([CI=1.05-1.89], p=0.02). 
Variable estimates that significantly reduced inpatient cost included:  (1) 
Treatment type, where chemotherapy only treatment is 0.26 times the inpatient billed cost 
of chemotherapy and HCT treatment, ([CI=0.16-0.40], p<.0001), and 0.30 times the 
inpatient standard cost of chemotherapy and HCT treatment, ([CI=0.20-0.45], p<.0001); 
(2) Severity level, where level 1 severity is 0.30 times the inpatient billed cost of level 4 
severity, ([CI=0.17-0.55], p<.0001) and 0.28 times the inpatient standard cost of level 4 
severity, ([CI=0.17-0.49], p<.0001) and level 2 severity is 0.53 times inpatient billed cost 
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of level 4 severity, ([CI=0.39-0.73], p<.0001) and 0.55 times inpatient standard cost of 
level 4 severity, ([CI=0.41-0.74], p<.0001); (3) Provider type, where a community 
provider had 0.71 times the inpatient billed cost of an academic provider, ([CI=0.53-
0.97], p=0.03) and 0.73 times the inpatient standard cost of an academic provider, 
([CI=0.55-0.95], p=0.02); (3) Age, where a one year increase in age resulted in 0.98 
times inpatient billed cost, ([CI=0.98-0.99], p<.0001), and had the same result for 
inpatient standard cost; and (4) Length of follow up, where a one day increase in the 
length of follow up resulted in 0.99 times inpatient billed cost, ([CI=0.99-1], p=0.04) and 
0.99 times inpatient standard cost, ([CI=0.99-1], p=0.05), but was only just significant in 
both models. 
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Table 4.11. Estimated Results for Inpatient Cost.  
 
 
 
 
1Results in bold are significant in the model 
2Severity level 3 and 4 are combined 
*Significant at α=.05 
 
 
4.2.4. Outpatient cost.  
 
The estimated results for outpatient cost are presented in Table 4.12. In the full 
model variable estimates that significantly increased outpatient cost included:  (1) 
Gender, where male gender is 1.31 times the outpatient billed cost compared to female 
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gender, ([CI=1.05-1.66], p=0.02) and 1.30 times the outpatient standard cost compared to 
female gender ([CI=1.04-1.63], p=0.02); and (2) Length of follow up, where a per day 
increase in length of follow up was 1.001 times the outpatient billed cost, ([CI=1.001-
1.002], p=<.0001) with the same result in outpatient standard cost.  
Variable estimates that significantly reduced outpatient cost included:  (1) 
Treatment type, where chemotherapy only treatment type is 0.20 times the outpatient 
billed cost of chemotherapy and HCT, ([CI=0.12-0.33], p<.0001) and 0.19 times 
outpatient standard cost of chemotherapy and HCT, ([CI=0.11-0.32], p<.0001); (2) 
Severity level, where severity level 1 is 0.31 times outpatient billed cost of severity level 
4, ([CI=0.19-0.50], p<.0001), and 0.32 times the outpatient standard cost of severity level 
4, ([CI= 0.2-0.51], p<.0001), severity level 2 is 0.48 times outpatient billed cost of 
severity level 4, ([CI=0.34-0.67], p<.0001) and 0.47 times outpatient  standard cost of 
severity level 4, ([CI=0.34-0.67], p<.0001, and severity level 3 is 0.63 times outpatient 
billed cost of severity level 4, ([CI=0.44-0.91], p=0.02) and 0.64 times outpatient 
standard cost of severity level 4 ([CI=0.44-0.92], p=0.02); (3) Provider type, where a 
community provider is 0.55 times the outpatient billed cost of an academic provider, 
([CI=0.44-0.71], p<.0001) and 0.56 times the outpatient standard cost of an academic 
provider, ([CI=0.44-0.71], p<.0001); and (4) Age, where a one year increase in age is 
0.99 times outpatient billed cost, ([CI=0.99-0.99], p=0.002) with the same result in 
outpatient standard cost and; (5) Provider % under poverty where a 1% increase in the 
rate of provider % under poverty is 0.97 times outpatient billed cost, ([CI=0.96-0.99], 
p=0.02) with the same result in outpatient standard cost. 
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Variable estimates that were not significant in the model include:  (1)  Payer type, 
where a commercial payer is 0.95 times the outpatient billed cost of a public payer, 
([CI=0.75-1.20], p=0.70) and 0.99 times the outpatient standard cost, ([CI=0.76-1.22], 
p=0.76), but was not significant in both models; and (2) Patient county % under poverty 
where, a 1% increase in the county % under poverty is 1.007 times outpatient billed cost, 
([CI=0.98-1.03], p=0.51) and but is 0.99% ,a decrease, of outpatient standard cost, 
([CI=0.98-1.03], p=0.53). 
In the reduced model the two variables with estimates that contributed to an 
increase in outpatient cost:  (1) Gender, where male gender was 1.32 times the outpatient 
billed cost of female gender, ([CI=1.05-1.64], p=0.02) and 1.30 times the outpatient 
standard cost of female gender, ([CI=1.04-1.64], p=0.02); and (2) Length of follow up, 
where a per day increase in length of follow up was 1.001 times the outpatient billed cost, 
([CI=1.001-1.002], p<.0001) with the same result for outpatient standard cost. 
The variable estimates that contributed to a decrease in outpatient cost included:    
(1) Treatment type, where chemotherapy only treatment is 0.20 times the outpatient billed 
cost of chemotherapy and HCT, ([CI=0.12-0.33], p<.0001) and 0.19 times the outpatient 
standard cost of chemotherapy and HCT, ([CI=0.12-0.32], p<.0001); (2) Severity level, 
where severity level 1 is 0.31 times the outpatient billed cost of severity level 4, 
([CI=0.19-0.49], p<.0001) and 0.32 times the outpatient standard cost of severity level 4, 
([CI=0.20-0.51], p<.0001), severity level 2 is 0.47 times the outpatient billed cost of 
severity level 4, ([CI=0.34-0.66], p<.0001) with the same result in outpatient standard 
cost and, severity level 3 is 0.63 times the outpatient billed cost of severity level 4, 
([CI=0.43-0.90], p=0.01) and 0.64 times the outpatient standard cost of severity level 4, 
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([CI=0.44-0.92], p=0.02); (3) Provider type, where a community provider is 0.56 times 
the outpatient billed cost of an academic provider, ([CI=0.44-0.71], p<.0001) and 0.56 
times the outpatient standard cost of an academic provider, ([CI=0.44-0.71], p<.0001) 
and; (4) Provider % under poverty, where  a 1% increase in the rate of % under poverty is 
0.97 times the outpatient billed cost ([CI=0.96-0.99], p=0.02) with the same result in 
outpatient standard cost. 
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Table 4.12. Estimated Results for Outpatient Cost. 
 
 
 
1Results in bold are significant in the model 
*Significant at α=.05 
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4.2.5. Pharmacy cost.  
The estimated results for pharmacy costs are presented in Table 4.13.  
The pharmacy cost models had the largest differences between billed cost and standard 
cost results.   In the full model, variable estimates that significantly increased pharmacy 
costs included: (1) Gender, where billed cost only, male gender is 1.47 times pharmacy 
cost compared to female gender, ([CI=1.03-2.09], p=0.03) and; (2) Length of follow up, 
where a per day increase in length of follow up is 1.001 times pharmacy billed cost  
([CI=1-1.002], p=0.002) and had the same result in pharmacy standard cost. 
Variable estimates that significantly reduced pharmacy costs included:   (1) 
Severity level, where level 1 severity is 0.45 times the pharmacy billed cost of severity 
level 4, ([CI=0.22-0.92], p=0.03) and 0.42 times the pharmacy standard cost of severity 
level 4, ([CI=0.21-0.84], p=0.01), level 2 severity is 0.59 times the pharmacy billed cost 
of severity level 4, ([CI=0.37-0.94], p=0.03) and 0.60 times the pharmacy standard cost 
of severity level 4, ([CI=0.39-0.94], p=0.03) and severity level 3, standard cost only, is 
0.60 times the pharmacy cost of severity level 4, ([CI=0.37-0.97], p=0.04) and; (2) 
Provider type, where a community provider, in standard cost only, is 0.67 times the 
pharmacy cost of an academic provider, ([CI=0.46-0.97], p=0.04); and (3) Provider % 
under poverty, standard cost only, where a one percent increase in the rate of % under 
poverty is 0.96 times the pharmacy standard cost, ([CI=0.93-0.99], p=0.01). 
Variable estimates not significant in the full model include:  (1) Gender, standard 
cost only, where male gender is 1.33 times pharmacy cost compared to female gender, 
([CI=0.95-1.87), p=0.09); (2) Severity level 3, billed cost only, is 0.66 times the 
pharmacy cost of severity level 4, ([CI=0.40-1.1], p=0.11); (3) Treatment type, where 
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chemotherapy only treatment is 0.91 times the pharmacy billed cost of chemotherapy and 
HCT, ([CI=0.47-1.76], p=0.79) and 0.83 times the pharmacy standard cost, ([CI=0.44-
1.55], p=0.5 6); (4) Payer type, where a commercial payer was 1.25 times the pharmacy 
billed cost than a public payer, ([CI=0.87-1.80], p=0.22) and 1.39 times the pharmacy 
standard cost, ([CI=0.99-1.07], p=0.06); (5) Patient county % under poverty, where a 1% 
increase in patient county % under poverty is 1.02 times pharmacy billed cost, ([CI=0.98-
1.06], p=0.3) and 1.02 times pharmacy standard cost, ([CI=0.99-1.07], p=0.16); (6) 
Provider type, billed cost only, where a community provider is 0.73 times the pharmacy 
billed cost of an academic provider, ([CI=0.50-1.08], p=0.12); and (7) Provider % under 
poverty, billed cost only, where a one percentile increase in the rate of provider % under 
poverty is 0.96 times the pharmacy billed cost, ([CI=0.94-1.05], p=0.05).  
In the reduced pharmacy cost model, two variable estimates significantly 
increased pharmacy cost:  (1) Age, where a per year increase in age is 1.02 times the 
pharmacy billed cost, ([CI=1.01-1.03], p=<.0001) and is 1.01 times pharmacy standard 
cost, ([CI=1.01-1.02], p<.0001); and (2) Length of follow up, where a per day increase in 
length of follow up is 1.002 times the pharmacy billed cost, ([CI=1.001-1.002], p<.0001) 
up is <1.001 times pharmacy standard cost, ([CI=1-1.002], p=0.02).   
Variable estimates that decreased pharmacy standard cost included:  (1) Severity 
level, standard cost only, where severity level 1 is 0.34 times the pharmacy standard cost 
of severity level 4, ([CI=0.17-0.67], p=0.002), severity level 2 is 0.60 times the pharmacy 
standard cost of severity level 4, (CI=0.39-0.93], p=0.02) and, severity level 3 is 0.59 
times the pharmacy standard cost of severity level 4, ([CI=0.35-0.96], p=0.03); (2) 
Provider type, standard cost only, where a community provider cost is 0.62 times the 
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pharmacy standard cost of an academic provider, ([0.44-0.89], p=0.01); and (3) Provider 
% under poverty, standard cost only, where a 1 % increase in the provider % under 
poverty rate is 0.95 times the pharmacy standard cost, ([CI=0.93-0.98], p=0.002).  
Gender is not significant in the reduced model.   
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Table 4.13. Estimated Results for Pharmacy Cost.  
 
 
1Results in bold are significant in the model 
*Significant at α=.05 
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4.2.6. Professional cost.  
The estimated results for the professional cost are presented in Table 4.14. In the 
full model only length of follow up increased professional costs where the  per day 
increase in length of follow up is 1.001 times professional billed cost, ([CI=1.001-1.002], 
p<.0001), and 1.002 times professional standard cost, ([CI=1.002-1.003], p<.0001). 
 Variable estimates that significantly reduced professional costs included:  (1) 
Treatment type, where chemotherapy only treatment is 0.19 times the professional billed 
cost of chemotherapy and HCT, ([CI=0.11-0.34], p<.0001) and 0.22 times the 
professional standard cost of chemotherapy and HCT, ([CI=0.12-0.37]), p<.0001); (2) 
Severity level, where severity level 1 is 0.44 times the professional billed cost of severity 
level 4, ([CI=0.28-0.69], p=0.0003) and 0.48 times the professional standard cost of 
severity level 4, ([CI=0.31-0.72], p=0.0006) and, severity level 2 is 0.44 times the 
professional billed cost of severity level 4, ([CI=0.32-0.6], p<.0001) and is 0.46 times the 
professional standard cost of severity level 4, ([CI=0.34-0.63], p<.0001); and (4) Age, 
where a per year increase in age is 0.98 times the professional billed cost, ([CI=0.98-
0.99], p<.0001), with the same result for professional standard cost. 
 Variable estimates that were not significant in the full model included:  (1) 
Gender, where male gender is 1.24 times the professional billed cost, ([CI=0.99-1.55]), 
p=0.05) and 1.21 times professional standard cost, ([CI=0.98-1.5], p=0.08); (2) Severity 
level 3 is 0.78 times the professional billed cost of severity level 4, ([CI=0.55-1.12], 
p=0.19) and 0.82 times the professional standard cost of severity level 4, ([CI=0.58-1.17], 
p=0.28); (3) Payer type, where a commercial payer is 0.95 times the professional billed 
cost of a public payer, ([CI=0.75-1.19], p=0.67) and 0.93 times the professional standard 
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cost of a public payer, ([CI=0.74-1.17], p=0.56); (4) Patient county % under poverty, 
where a 1% increase in county % under poverty is 0.99 times professional billed cost, 
([CI=0.97-1.02], p=0.94), and 0.99 times professional standard cost, ([CI=0.97-1.02], 
p=0.66); (5) Provider type, where a community provider is 0.98 times professional billed 
cost, ([CI=0.97-1.003], p=0.1) and 0.99 times professional standard cost, ([CI=0.97-
1.008], p=0.31); and (6) Provider % under poverty, where a 1% increase in the provider 
% under poverty rate is 0.98 times professional billed cost, ([CI=0.97-1.003], p=0.1) and 
0.99 times professional standard cost, ([CI=0.97-1.008], p=0.31). 
 In the reduced model, the variable estimate that increased professional cost is 
length of follow up, where a per day increase in the length of follow up is 1.002 times 
professional billed cost, ([CI=1.002-1.003]), p<.0001) with the same result for 
professional standard cost.   
Variable estimates that resulted in a cost reduction were: (1) Treatment type, 
where chemotherapy only treatment is 0.20 times the professional billed cost of 
chemotherapy and HCT, ([CI=0.11-0.33], p<.0001) and 0.22 times the professional 
standard cost of chemotherapy and HCT, ([CI=0.12-0.36], p<.0001); and (2) Severity 
level, where severity level 1 is 0.45 times the professional billed cost of severity level 4, 
([CI=0.32-0.65], p<.0001) and 0.47 times the professional standard cost of severity level 
4, ([CI=0.34-0.67], p<.0001) and severity level 2 is 0.49 times the professional billed cost 
of severity level 4, ([CI=0.39-0.62], p<.0001) and 0.51 times the professional standard 
cost of severity level 4, ([CI=0.41-0.63], p<.0001). 
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Table 4.14. Estimated Results for Professional Cost.  
 
 
 
 
1Results in bold are significant in the model 
2Severity level 3 and 4 are combined 
*Significant at α=.05 
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4.3. Results of the Hierarchical Model. 
 The hierarchical model (HM) analyzes the third specific aim of the study:  to 
investigate if patient and community enabling variables have added influence on cost 
over and above patient predisposing characteristics and patient need for services.  The 
model was run using the total cost criterion data only and results are presented in Table 
4.15. The hierarchical model was set up with three parts:  (1) A model which included 
only the patient predisposing characteristics of age, gender, length of follow up and the 
need for services variables of treatment type and severity level and; (2)  A model which 
included all variables included in the study:  the predisposing characteristics of age, 
gender and length of follow up, the need for services variables of treatment type and 
severity level and the patient and community enabling variables of payer type, county % 
under poverty, provider type and provider % under poverty and; (3) A reduced model 
which included only those variables that were significant in the full model. 
 The first model of patient predisposing characteristics and need for services 
variables resulted in significant estimates for all variables with the exception of severity 
level 3 and included:  (1) A per year increase in age is estimated to be 0.99 times the total 
billed and total standard cost outcome, ([CI=0.99-0.99]), p=0.0001) and ([CI=0.99-0.99], 
p=0.001) respectively; (2) Male gender is estimated at 1.78 times the cost outcome of 
female gender in billed cost and 1.68 times the cost outcome of female gender in standard 
cost, (CI=1.37-2.29], p<.0001) and (CI=1.29-2.18], p<.0001).  However, while there is a 
significant p-value, the confidence intervals are wide and the estimate is not reliable; (3) 
A per day increase in length of follow up in the datamart estimated a 1.001 increase in the 
cost outcomes, ([CI=1-1.001], p<.0001) and ([CI=1.001-1.002]. p<.0001); (4) 
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Chemotherapy only treatment was estimated to be 0.12 times the billed cost outcome of 
chemotherapy and HCT and 0.13 times the standard cost outcome of chemotherapy and 
HCT, ([CI=0.05-0.21], p<.0001) and (CI=0.06-0.23], p<.0001), indicating a large 
difference between the treatment groups.  Confidence intervals were in an acceptable 
range; and (5) Severity levels 1 and 2 were significant in both the billed cost and standard 
cost models.  Level 1 estimates are 0.35 times the level 4 billed cost, ([CI=0.21-0.59], 
p<.0001) and 0.34 times level 4 standard cost, ([CI=0.02-0.58], p<.0001).  Level 2 
estimates are 0.36 times level 4 billed cost, ([CI=0.25-0.51], p<.0001), and 0.38 times 
standard cost, ([CI=0.26-0.54], p<.0001).  Confidence intervals were in an acceptable 
range.  Level 3 severity was not significant in the model. 
 The full model added the patient and community enabling resources to the 
analysis, patient county % under poverty, payer type, provider type and provider % under 
poverty.  Of these additional variables, only provider type was significant where a 
community provider is estimated to be 0.68 times billed cost, ([CI=0.51-0.89], p=.007) 
and 0.67 times standard cost, ([CI=0.50-0.88], p=0.006).   
 The reduced model incorporated all significant variables from the full model; age, 
gender, length of follow up, treatment type, severity levels 1 and 2 and provider type and 
had the same result as the total cost predictive variables model where:  (1) Gender has a 
large influence with male costs 1.75 times the billed cost of females ([CI=1.36-2.27], 
p<.0001) and 1.66 times the standard cost of females ([CI=1.28-2.15), p=0.0001), 
however the confidence intervals are wide and therefore the estimate may not be reliable; 
(2)  A per year increase in age is 0.98 times billed cost, ([CI=0.98-0.99], p<.0001) and 
0.99 times standard cost, ([CI=0.98-0.99], p=0.0007); (3) A per day increase in the length 
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of follow up increased billed cost by 1.001 times, ([CI-1.001-1.002], p<.0001) and had 
the same result for the standard cost outcome, (4) Chemotherapy only is 0.13 times the 
billed cost of chemotherapy and HCT, ([CI=0.06-0.23], p<.0001) and 0.14 times the 
standard cost of chemotherapy and HCT, ([CI=0.06-0.26], p<.0001); and (5) Severity 
levels 1 and 2 were significant in the model, however the variable continued to have a 
problem with wide confidence intervals.  Severity level 1 is 0.44 times the billed cost of 
severity level 4, ([CI=0.28-0.70], p=0.0003) and 0.41 times the standard cost of severity 
level 4, ([CI=0.26-0.62], p=0.0002).  Severity level 2 is 0.44 times the severity level 4 
billed cost outcome, ([CI=0.33-0.58], p<.0001) and 0.45 times the severity level 4 
standard cost outcome and; (6) Provider type is the only community enabling resource 
included in the reduced model. A community provider cost is 0.73 times the billed cost 
([CI=0.57-0.9], p=0.02) and 0.71 times standard cost ([CI=0.54-0.95], p=0.01).   
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Table 4.15. Estimated Results of the Hierarchical Model. 
 
 
 
 
1Results in bold are significant in the model       2Severity level 3 and 4 are combined          *Significant at α=.05 
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4.4. Summary of Study Results. 
 A summary of the study results are provided for predictor variable characteristics, 
criterion variable mean, the reduced models predictions and the hierarchical model 
predictions. 
4.4.1. Summary of predictor variable characteristics. 
 A summary of predictor variable characteristics for each cost criterion is 
presented in Table 4.16.   
Acute leukemia patient characteristics of the study sample are consistent with 
what is reported nationally (http://seer.cancer.gov).  Patient demographics were similar 
for each criterion with a mean age of either 27 or 28 and a higher percentage of males, 
ranging from 56%-66%, as expected from the higher rate of leukemia diagnoses in males.   
This is similar to Surveillance Epidemiology and End Results (SEER) statistics showing 
a higher percentage of men with acute leukemia diagnoses and a combination of a 
younger ALL population and an older AML population.   
The length of follow (LOF) up variable methodologically controls for systematic 
differences in dates of service available in the data as recommended by Diehr (Diehr, 
et.al, 1999).  In this sample, mean LOF ranged from 330-445 days and had a range of 0-
729.  Much of the date of service data indicated same day service, or a zero LOF.  Total 
and professional costs were larger samples and contain more of the zero LOF data 
resulting in lower means, 330 days and 354 days respectively.  Ongoing treatment is 
more likely to be seen in ancillary cost, mean 439 day, inpatient cost, mean 420 days, and 
outpatient cost, mean 388 days and would be expected to have a longer and more 
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consistent LOF.  The highest mean LOF present in pharmacy cost, mean 445 days, 
reflects a higher level of ongoing pharmaceutical use.  
Most of the patients were treated with chemotherapy only.  Treatment type is 
dominated by chemotherapy only, ranging from 94% - 97% in the total cost, outpatient 
cost, pharmacy cost and professional cost.  Ancillary cost and inpatient cost with slightly 
lower percentiles of 88% and 89% respectively, reflect the higher use of services by the 
HCT treated patients with males representing 63% of the HCT treatment type. 
Level of severity is not similar between costs. Severity is measured by 4 levels 
with1 as the lowest and 4 as the highest.  Higher levels of severity of illness and related 
hospitalization are reflected in the higher levels of severity in the hospital-based ancillary 
cost and inpatient cost which show a higher percentage of high/medium to high levels of 
severity, 38% and 51%.  Total cost, outpatient cost, pharmacy cost and professional cost 
show more low to low medium levels of severity, 57% to 65%. 
Patient % under poverty had little variation between the mean percentages with a 
limited range of 11.98% - 12.41%.  The % under poverty rate was collected from U.S. 
census data using the county zip code data from the WHIO datamart.  Patient zip code 
was available in the WHIO datamart at the county level only as part of data de-
identification.  Unfortunately, county level zip code data is very broad; limiting the 
strength of the patient poverty measure.    
There is a higher percentage of use of public payers in the acute leukemia 
population.  Payer type was similar in all costs and showed a higher percentile of public 
payers compared to commercial payers, 52% to 56%; a result different from the U.S. 
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census reported percentage of 31% of all Americans covered by public insurance in 2011 
(www.census.gov/hhes).    
The majority of acute leukemia patients receive care from a community provider 
only.  Provider type was similar in all costs with the majority of patients treated at a 
community provider only, 45% - 52%. However of the 839 provider available, only 792 
were identifiable, resulting in percentages of missing data ranging from 13% in inpatient 
cost to 24% in total cost.  Patient records with missing provider data were not used in 
analysis.  In addition, overall use of community providers is under represented due to 
coding all claims for a patient who used an academic center as ‘academic’.   
Providers that treat acute leukemia are located in areas with relatively low levels 
of poverty.  The provider % under poverty variable represents the U.S. census poverty 
rate of the zip code of the provider and had a mean range of 5.97%-6.70%.  Provider zip 
code was obtained through the contact information listed in the WHIO datamart.   
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Table 4.16. Summary of Predictor Variable Characteristics. 
Variables Total  
cost 
Ancillary 
cost  
Inpatient 
cost  
Outpatient 
cost  
Pharmacy 
cost  
Professional  
cost 
Predisposing 
characteristics 
      
Age, n 837 164 232 639 390 748 
Mean  27  28 27  27  27  27  
       
Gender, n (%) 837 164 232 639 390 748 
Male 470 (56) 102 (62) 153 (66) 365 (57) 232 (59) 419 (56) 
       
Length of follow up, 
n 
 
837 
 
164 
 
232 
 
639 
 
390 
 
748 
Mean  330 439  420   388  445  354  
Need        
Treatment type,  
n (%) 
 
 
837 
 
164 
   
232 
 
639 
 
390 
 
748 
Chemotherapy only 
 
810 (97) 145 (88) 206 (89) 612 (96) 365 (94) 722 (97) 
Chemotherapy and 
HCT 
27 ( 3) 19 (12) 26 (11) 27 ( 4) 25 (  6) 26 (  3) 
 
Severity, n (%) 
 
837 
 
164 
 
232 
 
639 
 
390 
 
748 
Low 95 (11) 10 (  6) 19 (12) 71 (11) 38 (10) 84 (11) 
Low/medium 445 (53) 53 (33) 92 (39) 338 (53) 185 (47) 405 (54) 
High/medium 152 (18) 40 (24) 60 (24) 131 (21) 84 (22) 138 (18) 
High 145 (17) 61 (37) 61 (25) 99 (15) 83 (21) 121 (16) 
Enabling resources       
Patient   
% under poverty, n 
 
837 
 
164 
 
232 
 
639 
 
390 
 
747 
Mean  12.36 12.43 11.98 12.23 12.40 12.41 
       
Payer type, 
 n (%) 
 
837 
 
164 
 
232 
 
639 
 
390 
 
748 
Commercial 400 (48) 72 (44) 102 (44) 309 (48) 173 (44) 352 (47) 
Public 437 (52) 92 (56) 130 (56) 330 (52) 217 (56) 396 (53) 
       
Provider type, n (%) 837  164 232 639 390 618 
Community 410 (49) 74 (45) 111 (48) 303 (47) 185 (47) 390 (52) 
Academic     
medical center 
228 (27) 64 (39) 90 (39)  194 (30) 140 (36) 228 (31) 
Not   determined 199 (24) 26 (16) 31 (13) 142 (23) 65 (17) 130 (17) 
       
Provider 
% under poverty, n  
 
638 
 
138  
 
201 
 
497 
 
325 
 
618 
Mean  6.35 5.97 6.10 6.41 6.70 6.44 
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4.4.2. Summary of criterion variable means. 
A summary of the mean of each criterion variable by cost type is presented in 
Table 4.17.  Both types of cost, billed and standard, are analyzed to determine if their 
model results are consistent.   
Billed costs to patients do not reflect actual costs of service and are, with the 
exception of ancillary cost, highly inflated.  Average standard total cost is 50% less than 
billed total cost with a mean of $43,379 versus $86,309, and represents a reduction 
between the charges to the patient versus a valuation of actual cost of services.  The 
differences support concerns regarding the lack of financial transparency within the 
health care sector.  
Mean standard ancillary cost is equivalent to mean billed ancillary cost; $4,123 
versus $4,101. Standard ancillary cost is based on relative value units, RVU’s, from the 
Medicare fee schedule and in this sample the hospital facility charges are not higher than 
the standard RVU rate.   
Mean standard inpatient cost is 48% lower than mean billed inpatient cost; 
$80,787 versus $155,435.   Inpatient cost is standardized using a per diem cost, calculated 
with the diagnosis-related group (DRG) and the length of stay, taking into account the 
facility type and whether major surgery occurred.  The differences between the mean 
billed cost and mean standard cost identify differences in what is charged to the patient 
versus an estimate of the actual cost of inpatient services. 
Mean standard outpatient cost is 61% lower than mean billed outpatient cost; 
$8,410 versus $21, 424.  Outpatient standard cost uses a percentage of the billed amount 
and is adjusted by a WHIO-specific conversion factor to approximate an allowed amount.   
119 
 
 
 
Mean standard pharmacy costs are 29% lower than mean billed cost, $17,078 
versus $24,108.  Pharmacy costs are standardized using the average wholesale price 
(AWP) for the National Drug Code (NDC), adjusted by the therapeutic category and 
generic status. 
Mean standard professional costs are 60% lower than mean billed costs; $6,491 
versus $16,077.  Professional cost also uses RVU’s to standardize cost and the variation 
represents differences between what is charged to the patient and the RVU rate from the 
Medicare fee schedule.   
Table 4.17. Summary of Criterion Variable Means. 
Criterion variable ($) Mean billed cost Mean standard cost 
 
Total cost 86,309 43,379 
Ancillary cost 4,101 4,123 
Inpatient cost 155,435 80,787 
Outpatient cost 21,424 8,410 
Pharmacy cost 25,108 17,078 
Professional cost 16,077 6,491 
 
4.4.3. Summary of reduced model predictions. 
  A summary of the reduced model predictions for billed cost, Table 4.18, and 
standard cost, Table 4.19, of each criterion variable is presented.   
4.4.3.1. Billed cost.   
Younger age is predictive of higher cost in the acute leukemia population; with 
the exception of pharmacy cost and is the only variable included in every billed cost 
reduced model.  A per year increase in age generally resulted in a cost reduction by an 
estimated 0.98-0.99 times the cost criterion, however pharmacy cost had an estimated 
increase in cost of 1.02 times.  In each of the reduced models, the confidence intervals are 
small and, except for ancillary cost, p-values were significant.  The result is opposite the 
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documented increase in healthcare cost with increasing age as described in Seshamani 
and Grey, and, Garrett and Martini reflecting the higher use and more aggressive 
treatment of younger patients within the acute leukemia population.  Pharmacy cost 
follows the trend of higher cost associated with increasing age (Seshamani & Grey, 2004; 
Garret & Martini, 2007).   .  
Male gender is significantly predictive of higher cost in total cost, inpatient cost, 
and outpatient cost.  Gender was not included in the ancillary cost and professional cost 
reduced models and was not significant in the pharmacy cost reduced model.  The gender 
estimates in total cost, inpatient and outpatient cost models indicated a significantly 
strong increase in cost for males ranging from 1.32 to 1.75 times female cost.  While the 
p-values were significant, the confidence intervals were wide for this variable making the 
specific estimate not reliable.  The result in this sample is opposite what is generally 
reported in healthcare utilization where females have been shown to have a higher 
utilization rate, and would be expected to have higher costs (Bertakis, et.al, 2000).   
Length of follow up has a small but significant impact on the cost criterion.  With 
the exception of ancillary cost, length of follow up significantly entered every reduced 
model and was significant in each of the models.  In total, outpatient, pharmacy and 
professional cost, length of follow up estimated a small per day increase in the costs with 
estimates ranging from 1, no change, to <1.001.  Inpatient cost showed a slight decline as 
follow up increased with an estimate of 0.99 times a per day increase.  Because this 
variable controls for systematic differences in length of follow up in the sample, the 
relative small effect indicates that these differences may not have a large influence on the 
overall cost criterion but should not be ignored.   
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Lower levels of severity show a large reduction in most costs.  Severity level 
entered every reduced model but pharmacy cost and is significant in every model except 
for ancillary cost severity level 1.  Lower levels of severity had a range of 0.3-0.53 times 
the cost of severity level 4 and with p-values that are strong and similar between the 
models.  The confidence intervals for this variable are wide making the estimates 
unreliable.  However, while a specific rate may not be easily identified, it can be 
concluded that lower levels of severity are significantly less costly than higher levels of 
severity with between a 47% to 70% reduction in cost. 
Patients treated with HCT experience significantly higher costs, up to 87% more 
than patients treated with chemotherapy only.  Treatment type estimates were significant 
and included in each cost with the exception of ancillary cost and pharmacy cost.  The 
significant estimates predicted the chemotherapy only cost ranging from 0.13 times to 
0.26 times the billed cost of patients treated with HCT.  The variable estimate is strongly 
significant in each model and had acceptable confidence intervals.   
Community provider costs can be up to 55% lower than academic medical 
centers; however the degree of reduction is dependent on the cost criterion.  Except for 
professional cost, provider type was included in all reduced models and was significant in 
each.  The estimated influence was mixed; it was strong in ancillary cost where a 
community provider cost is 0.45 times that of an academic provider.  However, its 
confidence interval is wide and the specific estimate is not reliable.  Total and outpatient 
estimates of 0.73 and 0.71 respectively indicated a moderate influence; the confidence 
intervals were better but still wide.  The outpatient estimate of 0.97 was small, but the 
confidence intervals were also small resulting in a more reliable estimate.   
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Table 4.18. Summary of Estimated Reduced Model Results for Billed Cost.  
 
4.4.3.2. Standard cost.  
Younger age is predictive of higher cost in the acute leukemia population; with 
the exception of pharmacy cost.  This result in the standard cost type is the same as the 
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result in the billed cost type.  Age is the only predictor variable that is present in each of 
the standard cost reduced models.  In general, age estimated a reduction in standard cost 
of 0.98-0.99 times per year increase in age, with the exception of pharmacy cost which 
increased with age at an estimated 1.01 times per year.  Age was not significant in the 
final ancillary cost model.  The confidence intervals in each of the significant models 
were small and the p-values were strong.  
Male gender is significantly predictive of higher cost in total cost, outpatient cost 
and pharmacy cost.  This result is different from the billed cost model in a few ways; the 
variable did not enter the inpatient cost model as it did for billed cost, its estimates were 
smaller for the models it did enter, and it was significant in pharmacy standard cost. The 
significant estimates followed a similar trend as in  billed cost  with total costs resulting 
in the highest estimate of a male gender cost being 1.66 times female cost, followed by 
outpatient cost of 1.30 times and finally pharmacy cost of 1.002.  However, only the 
pharmacy cost had confidence intervals small enough to consider the result reliable. 
 Length of follow up has a small but significant impact on all cost criterions.  This 
result is similar to that of billed cost; length of follow up is present in all reduced models 
with the exception of ancillary cost and was not significant in the inpatient cost reduced 
model.  In the standard total cost, outpatient cost, pharmacy cost and professional cost 
reduced models LOF estimated a small per day increase in cost outcome ranging from 
<1.001 – 1.002.  The confidence intervals were small for this variable. 
Lower levels of severity are predictive of lower cost.  Severity level 1 and level 2 
were significant in each of the models where both estimates resulted in a large reduction 
in the standard cost when compared to the severity level 4 cost and ranged from 0.24 
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times the level 4 cost in level 1 ancillary cost to 0.6 times the level 4 cost in level 2 
pharmacy cost.  While the p-values are strong, the confidence intervals are wide and the 
specific estimates are not strongly reliable.  Severity level 3 also estimated a reduction 
from severity level 4 costs in the ancillary cost, outpatient cost and pharmacy cost models 
and while p-values were significant, confidence intervals were, again, wide and the 
estimates are unreliable.  Overall the results are similar to those found in billed costs 
except for a notable difference in pharmacy cost.  In pharmacy billed cost, severity level 
did not enter the reduced model; however, in pharmacy standard cost all levels of severity 
entered the reduced model and all levels identified significantly lower costs compared to 
level 4.  It is important to clarify that pharmacy cost data does not include retail 
pharmacy costs, only costs associated with a clinical or hospital provider.  Differences 
between billed costs and standard costs may be attributed to patient pharmacy charges not 
reflecting hospital and clinic pharmacy cost efficiencies obtained through the use of 
lower cost generics, bulk purchasing, other contractual reductions in price or eligibility 
for the government’s 340B program, a program which reduces pharmacy cost to 
providers who serve disadvantaged populations (www.nachc.org). 
Patients treated with hematopoietic stem cell transplant (HCT) experience 
significantly higher costs, up to 86% more, than patients treated with chemotherapy only. 
Treatment type entered each of the reduced models with the exception of ancillary cost 
and pharmacy cost.  It estimated a large decrease in cost of treatment with chemotherapy 
only with estimates ranging from 0.14 times in the total cost to 0.30 times in the inpatient 
cost.  Similar to billed cost, all reduced models were strongly significant for this variable 
and confidence intervals are acceptable.  
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Community provider costs can be up to 54% less than academic medical centers, 
however the degree of reduction is dependent on the cost criterion.  Provider type 
significantly entered the models of total cost, ancillary cost, outpatient cost and pharmacy 
cost with estimates reducing the cost criterion by 0.71 times, 0.46 times, 0.97 times and 
0.62 times.  The confidence interval for outpatient cost was small; however, confidence 
intervals for the other estimates were wider making them less reliable.  Still it may be 
interpreted that in these costs, a community providers cost is significantly lower than an 
academic medical center provider.  This result is consistent with other studies that have 
reported higher cost of academic medical centers, (Hays, 2003; Yuan, et.al, 2000). 
Provider type results were different between standard cost and billed cost in two 
instances:  (1) A significant impact in inpatient billed cost but not in inpatient standard 
cost; and (2) A significant impact in pharmacy standard cost but not in the pharmacy 
billed cost. A possible explanation for the difference between inpatient cost types may be 
that while the same services have the same actual cost in both types of providers there is 
a significant difference between how the two provider types bill for those services.  
Differences between pharmacy costs may be explained by academic medical centers 
using newer, higher cost, non-generic drugs versus community providers or they may 
reflect more community provider participation in the reduced cost 340B program (Hay, 
2003; www.nachc.com). Interestingly, pharmacy billed charges to the patient were not 
significantly different by provider type and may be attributed to providers who 
experience cost efficiencies not passing on those reductions to the patient charges.   
Providers located in areas with higher poverty rates have significantly lower 
inpatient and pharmacy costs. Provider % under poverty significantly entered the reduced 
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models with an inpatient estimate of 0.73 and a pharmacy estimate of 0.95.  Both 
estimates are significant, but the inpatient cost confidence interval is moderately wide 
and makes the specific estimate less reliable.   Inpatient standard cost is calculated using 
a per diem cost, length of stay and the presence of surgery.  This finding may reflect 
disparities in clinical practice in areas of higher % under poverty levels and may be 
associated with differences in diagnosis, treatment, effective use of evidence based 
medicine and, ultimately, quality of care.  The acute leukemia patient population is 
regularly treated with chemotherapy and other high end pharmaceuticals.  The estimated 
lower pharmacy cost in higher poverty locations may be related to the higher use of 
generics or lower cost pharmaceuticals in these locations as well as a higher rate of 
participation in the 340B program which reduces pharmaceutical costs to providers 
serving disadvantaged populations (www.nachc.com).  From a different perspective, it 
may relate to a higher use of more expensive, higher cost pharmaceuticals in wealthier 
communities.   
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Table 4.19. Summary of Estimated Reduced Model Results for Standard Cost.  
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4.4.4. Summary of the hierarchical model results. 
Results of the hierarchical model (HM) are presented in Section 4.3 and Table 
4.15. 
Patient predisposing characteristics and need for services have a significant 
influence on the cost of care.  In this acute leukemia sample, increasing age is associated 
with decreasing cost, a finding different from what is generally observed, and men have 
higher costs when compared to women, also a result different from the population norm 
(Seshamani & Grey, 2004; Garret & Martini, 2007; Bertakis, et.al., 2007).  The length of 
follow up within the data set does have a slight influence on the cost outcome, and should 
be kept in the model to control for differences.  Type of treatment highly influences cost, 
with patients who receive HCT having significantly higher costs compared to patients 
receiving chemotherapy only.  Lower severity of the disease episode reduces the cost 
outcome when compared to higher levels of severity.   
Only type of provider was significant when patient and community enabling 
resources variables were added to the model.  A community provider costs were less than 
the costs of an academic medical center.  Results are similar between billed cost and 
standard cost.  All other enabling resource variables did not enter the total cost reduced 
model and did not significantly influence the cost outcome.     
The reduced model of total cost resulted in the same set of variables of age, 
gender, length of follow up, treatment type, severity level 1 and 2 and provider type and 
all were significant in the final model.  HM was performed for total cost only because of 
this redundancy in the reduced model results.  However, HM does identify the strong 
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influence of patient predisposing characteristics and need for services variables on the 
cost criterions.   
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CHAPTER 5:  Discussion 
 
 This study is a cross-sectional secondary analysis of WHIO insurance claims data 
for patients diagnosed with acute leukemia.  The primary objective was to investigate 
how patient and community factors influence health care claims cost from the State of 
Wisconsin.  A secondary objective was to evaluate whether patient and community 
enabling factors have added influence on cost over and above patient characteristics and 
need factors. An underlying objective of the study was to assess the type of data available 
in the WHIO datamart and its usefulness for cost research. This chapter will provide:  (1) 
An overview of the study findings; (2) Study limitations; and (3) Recommendations for 
future research. 
5.1. Discussion of Study Findings. 
Anderson’s basic model of health care utilization suggests that certain patient and 
community characteristics are considered to be predictive of a higher use of health care 
services (Andersen, 1968).  The model guides how to investigate the influence of a 
limited set of administrative variables on cost.  Because acute leukemia is a relatively 
uncommon disease holds promise to have high treatment costs the use of an 
administrative database is of interest because it is expected to contain a large enough 
sample of patients for the analysis of costs.  From the study results it can be concluded: 
(1) Predisposing characteristics of acute leukemia patients may not follow the commonly 
reported direction of cost where higher cost is associated with older age and female 
gender.  Instead their costs are expected to be higher in younger, male patients; (2) As 
expected, the need for service variables of treatment type and severity level influence cost 
and are significant cost drivers; (3) Community enabling resources of provider type and 
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provider location influence cost where academic medical centers are associated with 
higher cost and providers located in areas with higher poverty are associated with lower 
costs; both raise questions of equity in treatment offered to patients dependent on where 
they receive treatment; and  (4) Costs related to different service types cannot be assumed 
to follow similar predictive patterns and will subsequently have differences in 
interpretation.  Research involving cost estimation and cost effectiveness should clearly 
identify the type of service costs being analyzed. 
5.1.1. Influence of patient predisposing characteristics. 
As expected, this study has confirmed that certain patient characteristics are 
predictive of cost.  However, their influence on cost in an acute leukemia population was 
not always similar to what is more generally found.  Prior research has shown that as the 
age of the U.S. population increases, the utilization rate and cost of health care also 
increases (Seshamani & Grey, 2004; Garret & Martini, 2007).   As age increased in the 
acute leukemia sample the cost criterion decreased in all but pharmacy cost.  This may be 
attributed to a number of factors including more aggressive and costly treatment of 
younger patients as well as less treatment options and therefore lower cost for older 
patients.  Hematopoietic stem cell transplant (HCT) is not common in patients over 70 
years of age and both HCT and chemotherapy treatment becomes increasingly less 
aggressive in patients over the age of 60.  Interestingly, Zweifel and colleagues argue that 
age as a driver of higher cost becomes insignificant when proximity to death, and the 
resulting costs, is controlled for.  This study supports cost of treatment being the 
important cost driver rather than age (Zweifel, Felder, Werblow, 2004). 
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 Bertakis identified a gender difference in the use of healthcare services with 
women having a higher rate of use (Bertakis, et.al, 2000).  However, in this study men 
had higher costs; over 50% more in some instances.  The percentage of males in the study 
sample was comparable to the Surveillance Epidemiology and End Results (SEER) 
reported diagnosis population for the acute leukemia’s; 56% in the study sample versus 
SEER reported 58% in ALL and 53% in AML.   
5.1.2. Influence of patient need for services.  
The results of this study confirm the expected higher health care costs for acute 
leukemia patients associated with their high need for health care services.  A higher level 
of severity, related to more comorbidity, would be expected to increase the cost of care 
and this variable was significant in each cost service type.  Treatment type was 
significant in all models with the exception of ancillary cost and pharmacy cost and 
represents a major driver of cost.  Treatment with hematopoietic stem cell transplant 
(HCT) significantly increases the cost of care in all other service types; total, inpatient, 
outpatient and professional.  It is not unexpected that HCT influences cost, however, the 
strength of its influence, with costs up to 86% higher than chemotherapy only treatment 
was more than expected.  The result is consistent with HCT’s identification as the 
procedure with the most rapidly increasing cost between 2004 and 2007 and it is assumed 
that the cost will continue to increase over time (Stranges, et.al, 2009).  HCT cost has 
been reported in numerous articles with subjects ranging from cost effectiveness of 
different treatment options to its overall cost of treatment (Majhail, et.al, 2009; 
Westerman, et.al., 1996; Waters, et.al., 1998; Cordonnier, et.al., 2005; Lee et.al., 2000; 
Lin et.al., 2010).  Khera and colleagues provide a comparison of HCT economic studies 
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and identify the need for high quality measures of cost and value-based assessments 
(Khear, Zeliadt, & Lee, 2012).  This study provides a quality measure of cost; the 
challenge will be to link the cost to clinical outcome and to create a value measurement.  
Given that HCT is intended to be a life-saving treatment, usually of last resort, a quality 
adjusted life years (QALY) study could be designed to investigate the cost per year of life 
saved.  Advances in scientific knowledge have expanded its use to a variety of 
hematologic diseases, disorders as well as patients.  However, it’s extremely high cost 
makes it vulnerable to cost containment processes.  In order to insure that this type of 
treatment is equitably offered based on clinical outcome rather than the ability to pay, 
valued-based research (i.e. value=cost+outcome) needs to be used to support well-
informed policy decision making. 
5.1.3. Influence of community enabling resources.  
  An important finding of this study is that the community enabling variables 
provider type and provider location influence some costs.  In Anderson’s model, 
socioeconomics is considered a factor that may impact how patients use heath care 
services where higher socioeconomic status is related to factors that support higher 
utilization, (i.e. if a healthcare provider is located in the community, all services are 
easily accessible, if there are preventive services, etc.).  In this study, the rate of poverty 
around the location of the provider is a socioeconomic measure of differences between 
providers located in areas with higher poverty versus providers located in wealthier areas. 
The provider % under poverty variable estimate was significant in both inpatient standard 
cost and pharmacy standard cost and resulted in a cost reduction where lower costs were 
associated with providers located in areas of higher levels of poverty.  
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 Inpatient costs are standardized using a per diem cost calculated with the factors 
of; diagnosis related group (DRG), length of stay, facility type and presence of major 
surgery.  Provider percent under poverty uses the U.S. census defined % under poverty 
rate identified through the zip code of the provider.  Reduced costs in areas of higher 
poverty would reflect a reduction in any one of the defined factors of; lower cost DRG’s, 
shorter length of stays, lower cost facility types and less major surgery or some 
combination.  A study by Billings and colleagues identified higher hospitalization rates in 
low-income areas due to less timely and effective outpatient care; however, this study 
found the opposite result for inpatient cost (Billings, Zeitel, Lukomnik, Carey, Blank, & 
Newman, 1993).  Whereas it is not in the scope of this study to assess the type of health 
care services provided at different provider locations, future work could investigate 
possible differences in the types of services provided, the provider’s availability to offer 
certain services, and whether access to needed health care services is compromised in low 
income areas.   
In the pharmacy cost sample lower standard cost is also associated with higher 
levels of poverty of the provider’s location.  Pharmacy costs are standardized using the 
average wholesale price from the National Drug Code (NDC), adjusted by therapeutic 
category and generic status.  Pharmacy costs in this study did not include retail pharmacy 
costs.  Using the standardization definition, a reduction in pharmacy cost would be 
associated with either different therapeutic categories, use of more generic statuses or 
participation in the 340B Drug Pricing Program where drug manufacturers provide a 
reduced 340B price for covered outpatient drugs to certain safety net providers who 
participate in the program.  Safety net providers include health centers receiving grant 
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funding under Section 330 of the Public Health Service Act and similar centers.  Most 
providers in lower socioeconomic locations would be eligible for participation in this 
program and the National Association of Community Health Centers (NACHC) report 
that the program can help them save between 15%-60% on their prescription drug costs. 
(www.nachc.com/client/documents).  In this study, the lower pharmacy cost for providers 
in poorer locations may be a reflection of participation in this program.  Another 
interpretation of the finding is that providers in poorer locations offer fewer therapeutics, 
more generic drugs or some combination.  A potential use of WHIO data could be an 
assessment of differences in the type of services offered by provider location; the data 
may support research related to the socioeconomic influence on availability of care and 
access to care. Finally, it is concerning that the cost difference found in the pharmacy 
standard cost model is not present in the billed cost model and it appears that lower costs 
attained by the provider are not passed on to the consumer.    
5.1.4. Variation in type of service cost estimators. 
The study findings highlight the variation in predicted cost estimators between 
type of service, (i.e., total, ancillary, inpatient, outpatient, pharmacy and professional), 
resulting in sometimes significantly different interpretations.  Overall, results vary in both 
direction and degree of influence and are dependent on the type of services which creates 
the cost.  Only total cost and outpatient cost contained the same variables in the reduced 
standard cost model with estimators that followed the same direction and with similar 
influence.  Significant variables in the total and outpatient cost samples relate to many 
components of Anderson’s model with; the patient predisposing characteristic variables 
age and gender, the patient need for services variables treatment type and severity level, 
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and the community enabling resources variable provider type.  All other costs identified a 
mixed group of variables which significantly influenced the cost criterion.  The ancillary 
standard cost and professional standard cost reduced models resulted in the fewest 
number of significant variables, but did not include the same significant variables in the 
final models, creating differences in model interpretation.  For example, treatment type is 
significant in the professional cost sample, but not in the ancillary cost sample, and may 
be related to a larger number of health care professionals involved in HCT treatment, a 
higher cost of at least some of those professionals, as well as the longer treatment time.  
Whereas provider type was significant in the ancillary cost sample, but not in the 
professional cost sample, and estimated lower costs in community providers versus 
academic providers.  This finding is possibly related to differences in the facilities cost 
and staff labor cost, an interpretation supported by Hay’s article of hospital cost drivers 
(Hay, 2003).  Pharmacy cost contained the largest number of significant variables in the 
reduced model and resulted in variable estimates that did not always follow the same 
direction of the other costs.   
Overall, it can be concluded that there is inherent complexity in assessing cost 
drivers that cannot be addressed through investigating total costs alone.  All cost 
research, whether it relates to cost effectiveness, estimation or value, should thoughtfully 
determine what cost type is best for its design and then clearly define all costs that are 
included. 
A separate interest of this study was to investigate whether different cost types, 
billed and standard, would have similar patterns in their results. This question is 
considered important because of the difference in the cost perspective of the two; billed 
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cost represents what is charged to the patient or consumer perceived cost and standard 
cost is the expected actual cost of service or the hospital perceived cost.  Whereas billed 
cost and standard cost were similar in some service types there were large differences 
present for both inpatient cost and pharmacy cost.   
Because standard cost reduces variation caused by factors such as insurance 
contractual differences and regional billing practices it makes it easier to interpret the 
actual value of the cost result. This study’s findings defend standard cost as a more 
meaningful research variable.  Use of standard cost in research is discussed in the 
literature which consistently identifies it as providing a valuation of actual cost and more 
meaningful interpretation of findings (Finkler, et.al., 1982).  However, differences 
between billed and standard cost raise serious questions regarding the lack of 
transparency in healthcare costs to the consumer.  For example, lack of cost transparency 
may result in an inflated patient perception of cost and interesting questions may relate 
to; how the patient perceives cost and those perceptions behavioral impact on how they 
obtain healthcare services, how patients perceive the accessibility of higher cost 
providers, and ultimately the clinical outcomes of care they receive.  Questions like these 
have national healthcare political and policy implications. Finally, paid cost, a variable 
not available for use in this study but is present in the WHIO database, could provide a 
payer perspective of health care cost as well as relevant information regarding if and 
when patients change payer type.  This variable would define the amount actually paid by 
insurance for services, and along with the billed and standard cost, would provide a more 
complete picture of how costs operate within the healthcare sector. 
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5.2. Study Limitations. 
Limitations of this study include issues such as meaningfulness of data available 
in administrative databases, disease sample size limitations, and generalizability of results 
outside the State of Wisconsin. Research using the WHIO all payer claims data should be 
designed to accommodate these inherent limitations.  Administrative data will generally 
restrict both the type and scope of research questions that can be addressed.  Healthcare 
claims data has limitations due to data censoring related to the both the amount of 
available follow up and death, where time of death is unknown.  Finally, data collection 
issues outside of the researcher’s control, such as coding errors and diagnosis errors, may 
impact the data.   Limitations to the data include: 
All payer claims databases are constructed for operational administration and 
reimbursement of health care charges rather than research projects.  The WHIO data does 
not provide critical clinical outcomes which would allow the investigation of important 
questions related to healthcare value and quality of life. Comorbidity data relates only to 
that reported through insurance claims and may not be fully inclusive of other factors 
impacting health.  
About 6% of provider demographic information was not available in the datamart.  
This represented either State of Wisconsin providers that were unidentifiable or out of 
state providers.  Lack of provider information reduced the size of the analysis sample in 
all costs. 
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Patient zip code data were only available on the county level, reducing its 
specificity.  The variable was not significant in any of the models, but may have been too 
broad of a measure to identify differences.   
Because the dataset contains only two years of insurance claims data it is not 
possible to assess longitudinal cost results for this sample.  Costs of care for these 
diseases are expected to be high and a longer time frame would be of interest to assess 
longer term trends in cost. 
Given the limited patient demographic and clinical outcome information, there is 
an increased risk of sample size bias due to factors that were unavailable, (i.e. patient 
race). This may be particularly obvious for variables such as % under poverty, because of 
its broad measure and provider type, which contained missing data.  
Healthcare claims will contain censored data due to inherent differences in patient 
follow up or death.  While this study adjusted for censoring within the regression 
equations, more robust statistical methods should be explored to better handle differences 
in follow up.  In addition, a future model may choose to define length of follow up as a 
confounding variable rather than using the predisposing characteristic definition used in 
this study.   Finally, acquisition of survival data would need to be explored prior to an 
expansion of the statistical method to better handle censoring due to death. 
Study results do not reflect uninsured costs of treatment and are limited in 
regional scope.  This State of Wisconsin all payer claims dataset does not contain 
information from insurance claims from outside the state nor does it provide uninsured 
costs of treatment.  In September, 2011, the U.S. census bureau estimated that 16.3% of 
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the U.S. population was uninsured in 2010 and Stranges and colleagues report 
approximately 25% of hospital stays from 2004-2007 for HCT treatment were uninsured, 
raising a question of whether the overall uninsured percentage in patients with an acute 
leukemia diagnosis may be higher than that found in the general population (Stranges, 
et.al, 2009).  Finally, because this is a single State dataset, it may have limited 
generalizability to populations outside of the State of Wisconsin given regional variations 
in health care cost. 
5.3. Recommendations for Future Research. 
 A number of future research opportunities result from this study and include 
proposals to expand the current study dataset with increased years of data as well as 
additional types of claims along with proposals for investigating the potential to link the 
cost data to outcomes data.  A discussion of each is provided. 
 In order to address questions of value in health care it is necessary that a study 
include both cost and outcome.  Linking cost data to outcomes data such as mortality, 
comorbidity and quality of life would provide the necessary two components of the value 
equation; cost and outcome. While the WHIO data provides a large amount of cost data, 
it can only construct outcomes data as it relates to insurance claims; for example 
comorbidities are used to determine severity level.  However, because the calculated 
severity level is restricted to insurance claims it does not capture all pertinent clinical 
features of the patient.  It will be important to explore avenues to obtain outcomes data 
either through potential direct linkages to clinical datasets, such as State level mortality 
data, or through possible statistical methods available to relate group cost outcomes to 
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group clinical outcomes.  An example would be to investigate a relationship between the 
male gender cost outcomes to a male gender HCT survival outcome. 
 This study’s data is restricted to costs associated with an acute leukemia diagnosis 
due to both data availability and dataset size. Expanding this diagnosis based dataset to a 
dataset of all insurance claims for these patients would create a more complete record of 
health care use.  The acute leukemia population is expected to utilize health care 
resources at a higher rate, costs associated with all claims would provide important 
information about both the use of and cost of services not directly tied to the leukemia 
diagnosis.  It is important to note that the total amount of claims data for this group would 
be large and would require a high level of technical resources to manage the dataset. 
 WHIO refreshes the datamart every six month and new patient records are added 
or current patient records are extended. Adding future WHIO data to the study dataset as 
it become available would enhance the current data and create the ability to design 
longitudinal cost studies and creating a larger sample of HCT data.  Because cost studies 
of HCT are difficult due to small sample sizes, creating a dataset of HCT treatment cost 
would allow investigations of not only longitudinal cost outcomes and cost effectiveness 
analyses but would also provide support for cost comparison studies of HCT treatment 
versus non-HCT treatment.  As supported by this study, HCT costs are very high, having 
the ability to study them in more depth impacts questions related to value of care and 
ultimately healthcare decisions and policy.  In addition, because the cost of HCT is high 
and treatment type had a strong influence on cost, it will be important to assess cost 
predictors when HCT is not present.  Creating a dataset of chemotherapy only treatment 
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cost would allow the opportunity to investigate health care costs of an acute leukemia 
population without the dominance of HCT costs. 
 Further exploration of cost disparities findings related to academic medical center 
and community providers, the location of the provider and the potential of differences in 
use of evidence based medicine practices and quality of care. 
Sub-analyses of interactions between variables were not within the scope of this 
study; however, conceptually they may be important.  Because of the number of variables 
there are a large number of potentially important interactions.  For example, given the 
significant differences in provider type cost and the significance of treatment type, it 
would be of interest to investigate if there is a significant interaction between the two and 
to determine if treatment type is influencing the differences in provider type.  In fact, 
because of the strong treatment type cost finding, it would be of interest to explore its 
influence on many of the significant variables.  Rather than analyzing each interaction 
separately, a study design incorporating the use of structural equation modeling (SEM) 
should be explored.  SEM would allow a simultaneous investigation of the relationships 
between the variables and could be used to direct research toward analyses of the 
resulting significant relationships. 
 
 
 
 
 
 
143 
 
 
 
REFERENCES 
 
Aday, L.  (2001). Establishment of a conceptual base for health services research. 
 Journal of Health Services Research Policy, vol. 6 (3), 183-185.  
 
American Cancer Society. (2012). Cancer Facts & Figures 2012.   Atlanta: American  
 Cancer  Society.  Retrieved from 
http://www.cancer/org/acs/groups/content/@epidemiologysurveilance/ 
documents. 
 
American College of Physicians. (2011).  How Can Our Nation Conserve and Distribute 
 Health Care Resources Effectively and Efficiently? College of Physicians Policy 
 Paper, Philadelphia: American. Retrieved from 
http://www.acponline.org/advocacy/where_we_stand/policy/health_care_resource 
s.pdf. 
 
Andersen, R.M. (1968).  Behavioral Model of Families’ Use of Health Services. 
 Research Series No. 25, Center for Health Administration Studies, University of 
 Chicago. 
 
Andersen, R.M. (1995).  Revisiting the Behavioral Model and Access to Medical Care: 
Does It Matter?  Journal of Health and Social Behavior, vol. 36 (1), 1-10. 
 
Ashfaq, K., Yahaya, I., Hyde, C., Andronis, L., Barton, P., Bayliss, S., & Chen, Y.F. 
(2010). Clinical effectiveness and cost-effectiveness of stem cell transplantation 
in the management of acute leukemia: a systematic review. Health Technology 
Assessment, vol. 14 (54); DOI: 10.3310/htal4540. 
 
Baker, K .S., Davies, S. M., Majhail, N.S., Hassebroek, A., Klein, J.P., Ballen, K.K., 
Bigelow, C.L., Frangoul, H.A., Hardy, C.L., Bredeson, C., Dehn, J., Friedman, 
D., Hahn, T., Hale, G., Lazarus, H. M., LeMaistre, C.F., Lobreiza, F., Maharaj,  
D., McCarthy, P., Setterholm, M., Spellman, S., Trigg, M., Maziariz, R.T.,  
Switzer, G., Lee, S.J., Rizzo, J.D. (2009).  Race and Socioeconomic Status  
Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation.  
Blood, 15, 1543-1554. 
 
Basu, A.  (2005).  Extended generalized linear models: Simultaneous estimation of 
flexible link and variance functions.  The Stata Journal, 5 (4), 501-516. 
 
Basu, A., & Manning, W.G.  (2009).  Issues for the Next Generation of Health Care Cost 
Analyses.  Medical Care, vol. 47 (7, suppl 1), S109-S114. 
 
Basu, A., Manning, W.G., Mullahy, J.  (2004).  Comparing alternative models:  log vs. 
Cox proportional hazard?  Health Economics, 13, 749-765. 
 
144 
 
 
 
Bennett, C.L., Waters, T.M., Stinson, T.J., Almagor, O., Pavletic, Z., Taratolo, S., & 
Bishop, M.  (1999).Valuing clinical strategies early in development:  a cost 
analysis of allogeneic peripheral blood stem cell transplantation.  Bone Marrow 
Transplantation, vol. 24, 555-560. 
 
Barber, J., & Thompson, S. (2004). Multiple regression of cost data: use of generalized  
 linear models. Journal of Health Services Research & Policy, vol. 9 (4), 197-204. 
 
 
Bertakis, K.D., Azari, R., Helms, L.J., Callahan, E. J., & Robbins, J.A. (2000). Gender  
Differences in the Utilization of Health Care Services.  The  Journal of Family 
Practice, vol. 49 (2), 147-152. 
 
Billings, J., Zeitel, L., Lukomnik, J., Carey, T.S., Blank, A.E., & Newman, L.  (1993).  
Impact of Socioeconomic Status on Hospital Use in New York City.  Health 
Affairs, 12 (1), 162-173. 
 
Centers for Medicare & Medicaid Services.  (2012). NHE Fact Sheet.  Retrieved from 
https://www.cms.gov/NationalHealthExpendData. 
 
Chang, S., Long, S.R., Kutikova, L., Bowman, L., Finley, D., Crown, W.H. & Bennett,  
C.L.  (2004). Estimating the Cost of Cancer:  Results on the Basis of Claims Data 
Analyses for Cancer Patients Diagnosed with Seven Types of Cancer During 
1999-2000. Journal of Clinical Oncology, vol. 22 (17), 3524-3530. 
 
Clegg, L.X., Reichman, M.E., Miller, B.A., Hankey, B.F., Singh, G.K., Lin, Y.D., 
Goodman, M.T…. & Edwards, B.K. (2009). Impact of socioeconomic status  
on cancer incidence and stage at diagnosis: selected findings from the 
surveillance, epidemiology, and end results: National Longitudinal Mortality 
Study. Cancer Causes Control, vol. 20, 417-435. 
 
Cohen, J., Cohen, P., West, S., & Aiken, L.  (2003).  Applied Multiple  
 Regression/Correlation Analysis for the Behavioral Sciences, 3
rd
 edition. 
Mahwah, New Jersey:  Lawernce Earlbaum Associates, Inc. 
 
Cordonnier, C., Maury, S., Esperou, H., Pautas, C., Beaune, J., Rodet, M., Lagrange, 
J.L…. & Durand-Zaleski, I.  (2005).   Do minitransplants have minicosts? 
A cost comparison between myeloablative and nonmyeloablative allogeneic stem  
cell transplant in patients with acute myeloid leukemia.  Bone Marrow  
Transplantation, 36, 649-654. 
 
Costa, V., McGregor, M., Laneuville, P., & Brophy, J.M.  (2007). The Cost-Effectiveness 
of Stem Cell Transplantations from Unrelated Donors in Adult Patients with 
Acute Leukemia.  Value in Health, vol. 10 (4), 247-255. 
 
 
145 
 
 
 
Deschler, B., & Lubbert, M.  (2006). Acute Myeloid Leukemia: Epidemiology and 
Etiology.  Cancer, 107 (9), 2099-2107. 
 
Diehr, P., Yanez, D., Ash, A., Hornbrook, M., & Lin, D.Y.  (1999).   Methods for 
Analyzing Health Care Utilization Costs.  Annual Review Public Health, 20,  
125-44. 
 
Dodd, S., Bassi, A., Bodger, K., & Williamson, P.  (2006). A comparison of 
Multivariable Regression models to analyze cost data.  Journal of Evaluation in 
Clinical Practice, 12(1), 76-86. 
 
Fielding, A.K., Richards  S.M., & Chopra, R.  (2007). Outcome of 609 adults after 
Relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 
study.  Blood, 109, 944-950. 
 
Finkler, S.  (1982). The Distinction between Cost and Charges.  Annals of Internal  
 Medicine, 96,102-109. 
 
Gajewski, J.L., Foote, M., Tietjen, J., Tietjen, J., Melson, B., Simmons, A., & Champlin 
R.  (2004). Blood and Marrow Transplantation Compensation: Perspective in 
Payer and Provider Relations. Biology of Blood and Marrow Transplantation, 10, 
427-432. 
 
Garrett, N., & Martini, E.M.  (2007). The Boomers Are Coming: A Total Cost of Care 
Model of the Impact of Population Aging on the Cost of Chronic Conditions in 
the United States.  Disease Management, 10 (2), 51-60. 
 
Geronimus, A., & Bound, J.  (1998).  Use of Census-based Aggregate Variables to Proxy 
for Socioeconomic Group:  Evidence from National Samples. American Journal 
of Epidemiology, vol. 14 (5), 475-486. 
 
Hann, I.M., Stevens, R.F., Goldstone, A.H., Rees, J.K.H., Wheatley, K., Gray, R.G., & 
Burnett, A.K.   (1997). Randomized comparison of DAT versus ADE as induction 
chemotherapy in children and younger adults with acute myeloid leukemia. 
Results of the Medical Research Council’s 10th AML Trial (MRC AML10). 
Blood, 89 (7), 2311-2318. 
 
Hay, J. (2003). Hospital Cost Drivers: An Evaluation of 1998-2001 State-Level Data. 
The American Journal of Managed Care, 9:SP13-SP24. 
 
Healthcare.gov, Report to Congress: National Strategy for Quality Improvement in 
Health Care: March 2011.   Retrieved from 
htttp://www.healthcare.gov/law/resources/reports. 
 
 
 
146 
 
 
 
Jacobs, P., Hailey, D., Turner, R., & MacLean, N.  (2000).   Allogeneic Stem Cell 
Transplantation An Economic Comparison of Bone Marrow, Peripheral Blood, 
and Cord Blood.  International Journal of Technology Assessment in Health 
Care, 16 (3), 874-884. 
 
Kaiser Family Foundation. (2011)  Health Care Spending in the United States and  
 Selected OECD Countries.  Retrieved from 
http://www.kff.org/insurance/snapshot/OECD042111.cfm. 
 
Kaiser Family Foundation. (2011). Summary of New Health Reform Law. Retrieved 
from http://www.kff.org/healthreform/upload/8061.pdf. 
 
Kantarjian, H.M., & O’Brien, S. (2009).  Insurance Policies in the United States may 
explain part of the outcome differences of adolescents and young adults with 
acute lymphoblastic leukemia treated on adult versus pediatric regimens. Blood, 
113, 1861. 
 
Kattan, M.W., Inoue, Y., Giles, F.G., Talpaz, M., Ozer, H., Guilhot, F., Zuffa, E., Huber, 
S.L., & Beck, J.R.  (1996). Cost-Effectiveness of Interferon-α and 
Conventional Chemotherapy in Chronic Myelogenous Leukemia.  Annals of 
Internal Medicine, 125 (7), 541-548. 
 
Khera, N., Zeliadt, S.B., & Lee, S.J.  (2012). Economics of hematopoietic cell  
 transplantation.  Blood, vol. 120 (8), 1545-1551. 
 
Kohler, B.A., Ward, E., McCarthy, B., Schymura, M.J., Ries, L.A., Eheman, C., Jemal, 
A…. & Edwards, B.K.  (2011). Annual Report to the Nation on the Status of  
Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System. 
Journal of the National Cancer Institute, 103 (9),1-23. 
 
Krieger, N., Chen, J.T., Waterman, P.D., Soobader, M.J., Subramanian, S.V., & Carson,  
R. (2002). Geocoding and Monitoring of US Socioeconomic Inequalities in 
Mortality and Cancer Incidence: Does the Choice of Area-based Measure and 
Geographic Level Matter?  American Journal of Epidemiology, vol. 156 (5), 471-
482. 
 
Krieger, N., Waterman, P.D., Chen, J.T., Soobader, M.J., Subramanian, S. V., & Carson,  
R. (2002). Zip code Caveat:  Bias due to Saptiotemporal Mismatches between Zip 
Codes and US Census-Defined Geographic Areas-The Public Health Disparities 
Geocoding Project.  American Journal of Public Health, vol. 92 (7), 1100-1102. 
 
Lee, S., Klar, N., Weeks, J.C., & Antin, J.H.  (2000). Predicting Costs of Stem-Cell 
Transplantation.  Journal  of Clinical Oncology, vol.18 (1), 64-71. 
 
Leukemia and Lymphoma Society.  Facts 2012. Retrieved from 
     www.lls.org/content/nationalcontent/resourcecenter/pdf/facts.pdf. 
147 
 
 
 
Lin, D.Y.  (2000). Linear regression analysis of censored medical costs.  Biostatistics, 1 
(1), 35-47. 
 
Lin, Y., Lairson, D., Chan, W., Du, S.L., Leung, K.S., Kennedy-Nassar, A.A., Martinez,  
 C.A…. & Krance, R.A.  (2010). The Costs and Cost-Effectiveness of 
Allogeneic Peripheral Blood Transplantation versus Bone Marrow 
Transplantation in Pediatric Patients with Acute Leukemia.  Biology of Blood and 
Marrow Transplantation, 16, 1272-1281. 
 
Majhail, N.S., Mothukuri, J.M, MacMillan, M.L, Vemeris, M.R., Orchard, P.J., & 
Weisdorf, D.J.  (2010). Costs of Pediatric  Allogeneic Hematopoietic-Cell 
Transplantation.  Pediatric Blood Cancer, 54, 138-143. 
 
Majhail, N.S., Mothukuri, J., Brunstein, C., & Weisdorf, D. (2009). Costs of  
Hematopoietic Cell Transplantation:  Comparison of Umbilical Cord Blood and 
Matched Related Donor Transplantation and the Impact of Posttransplant 
Complications.  Biology of Blood and Marrow Transplant, 15, 564-573. 
 
Manning, W. & Mullahy, J. (2001). Estimating log models:  To transform or not to 
transform?  Journal of Health Economics, 20, 461-494. 
 
Meropol, N.J., Schrag, D., Smith, T.J., Mulvey, T.M., Langdon, R.M. Jr., Blum, D.,  
Ubel, P.A., & Schnipper, L.E.  (2009). American Society of Clinical Oncology 
Guidance Statement; The Cost of Cancer Care. Journal of Clinical Oncology, 27 
(23), 3868-3874. 
 
Motheral, B., Brooks, J., Clark, M.A., Crown, W.H., Davey, P., Hutchins, D., & Martin, 
B.C.  (2003).  A Checklist for Retrospective Database Studies-Report of the 
ISPOR Task Force on Retrospective Databases. Value in Health, 6 (2), 90-97. 
 
Narayanan, S., & Shami, P.J.  (2011). Treatment of acute lymphoblastic leukemia in  
adults.  Critical Reviews in Oncology Hematology, 
doi:10.1016/j.critrevonc.2011.01.014. 
 
National Association of Community Health Centers. (2011). Understanding the 340B  
 Program: A Primer for Health Centers. Retrieved from http://www.nachc.com/. 
 
National Cancer Institute, Cancer Stat Fact Sheets.  Retrieved from 
http://seer.cancer.gov/statistics/. 
 
National Cancer Institute, Cancer Statistics Review 1975-2008. Retrieved from 
 http://srab.cancer.gov/prevalence/canques.html. 
 
National Cancer Institute, Cancer Trends Progress Report 2009/2010. Retrieved from 
 http//progressreport.cancer.gov/doc_detail.asp?pid 
 
148 
 
 
 
National Cancer Institute. The Cost of Cancer, 2010. Retrieved from 
 http://cancer.gov/aboutnci/servingpeople/cancer-statistics/costofcancer. 
 
National Marrow Donor Program, Understanding Your Treatment Options. Retrieved  
 from http://marrow.org/Patient/ Disease_and_Treatment/Treatment_Options. 
 
Neal, D.J. & Simons, J.S. (2007).  Inference in Regression Models of Heavily Skewed 
Alcohol Use Data:  A Comparison of Ordinary Least Squares, Generalized Linear 
Models, and Bootstrap Resampling.  Psychology of Addictive Behaviors, vol. 21 
(4), 441-442. 
 
Orsi, C., Bartolozzi, B., Messori, A., & Bosi, A.  (2007). Event-free survival and cost- 
effectiveness in adult acute lymphoblastic leukaemia in first remission treated 
with allogeneic transplantation. Bone Marrow Transplantation, 40, 643-649. 
 
Pasquini, M.C., & Wang, J.  (2011). Use and outcome of hematopoietic stem cell  
transplantation; CIBMTR Summary Slides.  Retrieved from 
http://www.cibmtr.org. 
 
Paulson, K., Szwajcer, D., & Steftel, M.D.  (2011). The role of allogeneic stem cell 
transplantation for adult acute lymphoblastic leukemia. Transfusion and 
Apheresis Science, 44, 197-203. 
 
Pickard, S., Topfer, L., & Feeny, D.  (2004).  A Structured Review of Studies on Health- 
Related Quality of Life and Economic Evaluation in Pediatric Acute 
Lymphoblastic Leukemia.  Journal of the National Cancer Institute Monographs, 
No. 33, 102-125. 
 
Pui, C.H. & Evans, W.E.  (2006). Treatment of Acute Lymphoblastic Leukemia. The 
New England  Journal of Medicine, 354, 166-78.  
 
Ramsey, S. & Schickedanz, A.  (2010). How Should We Define Value in Cancer Care?  
 TheOncologist,15 (suppl 1), 1-4. Retrieved from www.TheOncologist.com. 
 
Redaelli, A., Botteman, M.F., Stephens, J.M., Brandt & S., Pashos, C.L.  (2004).  
Economic burden of acute myeloid leukemia: a literature review. Cancer 
Treatment Reviews, 30, 237-247. 
 
Saito, A.M, Cutler, C., Zahrieh, D., Soiffer, R.J., Ho, V.T., Alyea, E.P., Koreth, J.… & 
Lee, S.J. (2008). Costs of Allogeneic Hematopoietic Cell Transplantation with 
High-Dose Regimens.  Biology of Blood and Marrow Transplantation, 14, 197-
207. 
 
 
 
 
149 
 
 
 
Saito, A.M, Zahrieh, D., Cutler, C., Ho, V.T., Antin, J.H, Soiffer, R.J., Alyea, E.P., & 
Lee,S.J.  (2007).  Lower costs associated with hematopoietic cell transplantation 
using reduced intensity vs. high-dose regimens for hematological malignancy. 
Bone Marrow Transplantation 40 (20),9-217. 
 
Statistics Calculators, Sample size.  Retrieved from http://daneilsoper.com/statcalc3/. 
 
Schafer, E.S. & Hunger, S. (2011). Optimal therapy for acute lymphoblastic leukemia in 
adolescents and young adults. Nature Reviews/Clinical Oncology, 8, 417-424. 
 
Sclar, D., Robison, L.M., Vavrun, C., Slaer. T. L.  (2008). Hospital length of stay for 
children and adolescents diagnosed with depression:  is primary payer an 
influencing factor?, General Hospital Psychiatry,30, 73-76. 
 
Schneeweiss, S,. & Avorn, J.  (2005). A review of uses of health care utilization  
Databases for epidemiologic research on therapeutics. Journal of Clinical 
Epidemiology, 58, 323-337. 
 
Seshamani, M., & Gray, A.  (2004). Ageing and health-care expenditure: the red herring 
argument revisited, Health Economics, 13(4), 303-314. 
 
Shi, Leiyui, ( 2008). Health Services Research Methods, 2nd edition. Clifton Park, New 
York: Delmar, Cengage Learning. 
 
Stanton, M. Reducing Costs in the Health Care System; Learning From What Has Been  
Done.  U.S. Department of Health & Human Services, Agency for Healthcare 
Research and Quality.  Retrieved   http://www.ahrq.gov/research/costsria/. 
 
Stephens, J.M., Gramegna, P., Laskin, B., Botteman, M., & Pashos, C.  (2005). Chronic 
Lymphocytic Leukemia: Economic Burden and Quality of Life. American 
Journal of Therapeutics, 12, 460-466. 
 
Stock, W., La, M., Sanford, B., Bloodfield, C.D., Vardiman, J.W., Gaynon, P., Larson,  
 R.A., & Nachman, J.  (2008). What determines the outcomes for adolescents and 
young adults with acute lymphoblastic leukemia treated on cooperative group 
protocols?  A comparison of Children’s Cancer Group and Cancer and Leukemia 
Group B Studies. Blood, 112, 1646-1654. 
 
Stranges, E., Russo, A., & Friedman, B.  (2009).  Procedures with the Most Rapidly 
Increasing Hospital Costs, 2004-2007. HCUP Statistical Brief #82.  December, 
2009. Agency for Healthcare Research and Quality, Rockville, MD.  Retrieved 
from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf.  
 
Tabachnick, B., & Fidell, L. (2001). Using Multivariate Statistics, 4
th
 edition. 
 NeedhamHeights, Massachusetts:  Allyn & Bacon. 
 
150 
 
 
 
U.S. Census Bureau. (2010). Income, Poverty and Health Insurance Coverage in the  
 United States:  2010.  Retrieved from  
http://www.census.gov/newsroom/releases/archives/income_wealth. 
 
U.S. Department of Labor, Bureau of Labor Statistics. (2010). Economic News Release:  
 Consumer Expenditures-2010.  Retrieved from 
http://www.bls.gov/news.release/cesan.nr0.htm. 
 
Van Litsenburg, R.R.L., Uyl-de Groot, C.A., Raat, H., Kaspers, G.J., & Gemke, R.J.  
(2011). Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic 
Leukemia with Chemotherapy Only: The Influence of New Medication and 
Diagnostic Technology. Pediatric Blood Cancer, DOI 10.1002/pbc.23197. 
Retrieved from www.wileyonlinelibrary.com. 
 
Vila, P.M., Swain, G.R., Baumgardner, D.J., Halsmer, S.E., Remington, P.L., & Cisler, 
R. A. (2007).  Health Disparities in Milwaukee by Socioeconomic Status.  
Wisconsin Medical Journal, 106 (7), 366-372. 
 
Waters, T., Bennett, C., & Pajeau, T.  (1998). Perspective:  Economic analyses of bone 
marrow and blood stem cell transplantation for leukemia’s and lymphoma:  what 
do we know?  Bone Marrow Transplantation, 21, 641-650. 
Westerman, I. & Bennett, C.  (1996). A review of the Costs, Cost-Effectiveness and 
Third-Party Charges of Bone Marrow Transplantation.  Stem Cells, 14, 312-319. 
 
Wisconsin Department of Health Services, Division of Public Health, Office of Health 
Informatics, Wisconsin Cancer Incidence and Mortality; 2002-2006.  Retrieved 
from  http://www.dhs.wisconsin.gov/wcrs/pdf/cancerwi0206. 
 
Wisconsin Health Information Organization, Our Members. Retrieved from 
http://www.wisconsinhealthinfo.org/. 
 
Wisconsin Health Information Organization, WHIO DMV6 training notes, 1-6-2012. 
 
Yu, Y.B., Gau, J.P., You, J.Y., Chern, H.H., Chau, W.K., Tzeng, C.H., Ho, C.H., & Hsu, 
H. C. (2007).   Cost-effectiveness of post-remission intensive therapy in patients 
with acute leukemia.  Annals of Oncology, 18, 529-534. 
 
Yuan, Z., Cooper, G., Einstadter, D., Cebul, R.D., & Rimm, A.A.  (2000). The  
Association between Hospital Type and Mortality and Length of Stay: A Study of 
16.9 Million Hospitalized Medicare Beneficiaries. Medical Care, 38 (2), 231-24. 
 
Zweifel, P., Felder, S., & Werblow, A. (2004).  Population Ageing and Health Care 
Expenditure:  New Evidence on the “Red Herring”.  The Geneva Papers on Risk  
and Insurance, vol. 29 (4), 652-666. 
 
151 
 
 
 
APPENDICIES 
Appendix A.  WHIO DMV6 Characteristics. 
Table A.  Characteristics of WHIO DMV6 data mart, WHIO lymphoma and leukemia, 
and WHIO acute leukemia population. 
Source:  WHIO DMV6 training notes 1-6-2012 
 
 
 
 
 
Variable WHIO WHIO Lymphoma/ 
Leukemia 
WHIO Acute 
Leukemia 
Population 3,863,345 12,504 837 
    
% WI Population 64.9% .3% .02% 
    
Age    
<18 29% 14% 50% 
18-64 58% 34% 39% 
65+ 13% 52% 12% 
    
Claim service records 247,620,120  271,121 
Medical  183,554,190 1,048,576 234,450 
Pharmacy   64,065,930 Not available 36,671 
    
Claim service record by 
payer type 
   
Private/commercially 
insured 
42% 32% 47% 
Public insured 58.1% 68% 53% 
Federal Employee 
Program 
0.1%   
Medicare 13%   
Medicaid 45%   
Unknown 1%   
    
Episodes of care 23.1M 18,324 8133 
    
Claims $ included (Billed 
cost/Std. cost) 
$64B/$34.4B $360M (billed) $46M/$23M 
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Table B.  Characteristics of acute leukemia analysis samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Total Ancillary Inpatient Outpatient Pharmacy Professional 
Sample, n 638 138 201 497 325 618 
       
% WI 
Population 
.01% .002% .003% .008% .005% .01% 
       
Age       
<18 49% 51% 52% 52% 54% 50% 
18-64 39% 40% 36% 36% 34% 39% 
65+ 12% 9% 12% 12% 12% 11% 
       
Male gender 56% 64% 66% 59% 62% 57% 
       
Claim service 
records 
262,524 3,869 19,683 111,488 36,671 99,410 
       
Claim service 
record by 
payer type 
      
Commercial 48% 46% 43% 48% 43% 47% 
Public insured 52% 54% 57% 52% 57% 53% 
       
       
Claims $ 
included 
(Billed/Std. 
cost) 
$44M/ 
$21M 
$672,577/ 
$676,253 
$15M/ 
$7.9M 
$6.9M/ 
$2.7M 
$7.4M/ 
$5M 
$11M/ 
$4.4M 
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Appendix B.  WHIO Definitions. 
Source:  Ingenix Reporting System User Guide; WHIO training materials; Vila, et.al, Health 
Disparities in Milwaukee by Socioeconomic Status, 2007. 
 
WHIO Episode Treatment Groups (ETGs):  ETGs are an illness classification method 
that combines medical and pharmacy services into mutually exclusive and exhaustive 
categories; providing a meaningful statistical unit representing an episode of care.  
WHIO severity level:  Severity is modeled per episode and uses the episode’s associated 
complications and comorbidities in addition to patient age and gender. 
Severity model markers, each is assigned a weight: 
 Age and gender 
 Co-morbidities and condition status 
 Treatments not used in severity model 
Severity score: 
 The sum of the weights for all markers 
 Relative to costs for the episode 
Severity level: 
 1-4; using score and preset ranges 
WHIO standard cost:  Standard cost is calculated with billed amount as input.  For 
inpatient services, the standard cost is based on a per diem cost calculated, primarily, 
with the DRG and length of stay in addition to facility type and presence of major 
surgery.  Professional and ancillary services standard cost is based on Relative Value 
Unit’s (RVU) from the Medicare Fee Schedule and pharmacy services standard cost uses 
the average wholesale price (AWP) for the National Drug Code (NDC), adjusted by 
therapeutic category and generic status.  Facility and outpatient claims are based on a 
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percentage of the billed amount and, in some cases, are adjusted by a WHIO-specific 
conversion factor to approximate a allowed amount.  
WHIO type of service:  Claims are categorized based on the major type of services and 
the procedure codes used in describing the service.  There are four major types of service 
used after assigning a service to these categories; CPT, HCPCs and Revenue codes are 
used to further differentiate services at each level.     
1.  Ancillary 
2.  Facility Inpatient 
3.  Facility Outpatient 
4.  Professional 
Pharmacy is the fifth service type used in the study:  all claims assigned to a pharmacy 
service code at any of the levels of type of service are specific to a drug cost and does not 
include procedures or administration of the drug. 
WHIO ZIP code:  The largest 5-digit ZIP code within a region that represents a 
population of >20K with the selection criteria of:  
 True county,  
 3-ZIP area excluding counties > 20K,  
 Full 3-ZIP area, 
 State 
All patients within the same region of the State are assigned the same ZIP-code for de-
identification purposes and the lowest level of patient geographic region identification is 
the county level.  A small number of patients from counties <20K are assigned to 
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neighboring counties, i.e. the largest 5-digit ZIP code in a 3-ZIP area that represents a 
population of >20K. 
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Appendix C.  WHIO DMV6 Data Information.  
Source:  WHIO DMV6 Impact Intelligence Training Notes, 1/6/2012 
Types of Data 
 
 Data includes combined Eligibility, Medical and Pharmacy Claims and Provider 
information from 15 health plans or other payers active in Wisconsin: Anthem, Dean, 
Group Health Cooperative of South Central Wisconsin, Gundersen Lutheran, Health 
Tradition Health Plan, Humana, MercyCare, Network Health Plan, Physicians Plus 
Insurance Corporation, Security, State of Wisconsin Medicaid (FFS and HMO), United 
HealthCare, Unity Health, Wisconsin Education Association Trust and Wisconsin 
Physicians Service. The aggregated data does not contain any proprietary payer 
information.  Data does not include lab results or patient satisfaction information. 
 Raw data includes all activity provided to Wisconsin members, regardless of 
whether the service was incurred by a Wisconsin provider, as well as all activity 
performed by Wisconsin providers, regardless of whether the member resides in 
Wisconsin. 
 Eligibility and claims information provided by data contributors is included in the 
WHIO datamart; exceptions are provided below.    
 There are a small percentage of non-Wisconsin members that are included in the 
WHIO data mart (e.g., from Border States, students, snowbirds) because they were 
identified as having a complete claims experience. Claims serviced by non-Wisconsin 
providers for some members of this group may be included. 
 All Wisconsin-related data is requested from data contributors including members 
with Commercial, fully insured and full medical coverage; Commercial ASO members; 
Medicare members administered by the data contributors; Medicare Supplemental 
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members; other non-Commercial full-coverage members; other Commercial or non-
Commercial partial-coverage members; and uncommon situations or other members. The 
ability of data contributors to send data beyond their core Commercial business is 
challenging and has varied by payer. 
 All Medicaid data is supplied by the State of Wisconsin only and include FFS and 
HMO members with full medical coverage, Medicare dual members with supplemental 
medical coverage through Medicaid, and a few members with Rx-only coverage. 
 Medicare supplemental or Medicare/Medicaid dual members are represented by 
only their non-Medicare data in the data mart unless their Medicare coverage is 
administered by a private carrier (i.e., Medicare Advantage members) and the private 
carrier is a WHIO data contributor.  When Medicare data is included for these members, 
the member’s eligibility for the overlapping eligibility period will reflect their full 
medical coverage through Medicare and any supplemental claim lines is categorized as 
pseudo claims. 
 Employee Trust Fund (ETF) members and claims are included. They are identified 
in the raw data but not in the final WHIO data mart to mask any member- or payer-
specific information.    
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Appendix D.  WHIO Provider Data. 
1.  Provider records. 
Provider information 
 
Number of provider records 
Total provider records 
 
837 
Identified Wisconsin provider records 
 
638 
Unidentified Wisconsin provider records 
 
121 
Out of state provider records 
 
53 
Unspecified provider records 25 
 
2.  U.S. State where care was provided. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. States with provider records 
ARIZONA 
CALIFORNIA 
GEORGIA 
ILLINOIS 
INDIANA 
IOWA 
KENTUCKY 
MASSACHUSETTS 
MICHIGAN 
MINNESOTA 
MISSOURI 
OHIO 
PENNSYLVANIA 
SOUTH DAKOTA 
TENNESSEE 
TEXAS 
WISCONSIN 
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Appendix E.  Dataset Coding. 
 
1.  Disease type (AML_ALL) code:  patients with a diagnosis of AML or ALL present in 
the database are coded as AML_ALL and included in the study population. 
 
Disease type Disease type code 
AML_ALL 1 
 
Other 0 
 
 
2.  Episode severity code: 
 
Episode severity Episode severity code 
Low 1 
 
Medium low 2 
 
Medium high 3 
 
High 4 
 
 
3.  Episode Treatment Group-ID: 
 
ETG type ETG-ID 
Leukemia without surgery 85 
 
Leukemia with surgery 86 
 
Leukemia with active management 
without surgery 
 
87 
Leukemia with active management 
with surgery 
88 
 
3.  Payer type code: 
 
Payer type Payer type code 
Commercial 
 
0 
 
Public 1 
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4.  Provider type code: 
 
Provider type Provider type code 
Community 
 
0 
Academic medical center 1 
 
 
5.  Service type code: 
 
Service type Service code 
Ancillary 
 
1 
Inpatient 
 
2 
Outpatient 
 
3 
Professional 
 
4 
Pharmacy 7 
 
 
6.  Treatment type code: 
 
Treatment type Treatment type 
code 
Chemotherapy only 
 
0 
Chemotherapy and HCT 1 
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